{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:15:20Z","timestamp":1793927720943,"version":"4.8.0"},"reference-count":286,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2019,4,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    is capable of becoming resistant to all classes of antibiotics clinically available and resistance can develop through\n                    <jats:italic>de novo<\/jats:italic>\n                    mutations in chromosomal genes or through acquisition of horizontally transferred resistance determinants. This review covers the most important antibiotics available for treatment of\n                    <jats:italic>S. aureus<\/jats:italic>\n                    infections and a special emphasis is dedicated to the current knowledge of the wide variety of resistance mechanisms that\n                    <jats:italic>S. aureus<\/jats:italic>\n                    employ to withstand antibiotics. Since resistance development has been inevitable for all currently available antibiotics, new therapies are continuously under development. Besides development of new small molecules affecting cell viability, alternative approaches including anti-virulence and bacteriophage therapeutics are being investigated and may become important tools to combat staphylococcal infections in the future.\n                  <\/jats:p>","DOI":"10.1128\/microbiolspec.gpp3-0057-2018","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T08:45:19Z","timestamp":1553244319000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":448,"title":["Antibiotic Resistance and the MRSA Problem"],"prefix":"10.1128","volume":"7","author":[{"given":"Martin","family":"Vestergaard","sequence":"first","affiliation":[{"name":"Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Frees","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Ingmer","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Boyle-Vavra S Daum RS. 2016. Molecular strategies of Staphylococcus aureus for resisting antibiotics p 249\u2013300. In Somerville GA (ed) Staphylococcus : Genetics and Physiology . Caister Academic Press Poole UK.","DOI":"10.21775\/9781910190494.11"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Haaber J Penad\u00e9s JR Ingmer H. 2017. Transfer of antibiotic resistance in Staphylococcus aureus . Trends Microbiol 25: 893\u2013905 http:\/\/dx.doi.org\/10.1016\/j.tim.2017.05.011. [PubMed]","DOI":"10.1016\/j.tim.2017.05.011"},{"key":"e_1_3_1_4_2","unstructured":"\u2022\u2022\u2022. In press."},{"key":"e_1_3_1_5_2","unstructured":"\u2022\u2022\u2022. In press."},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Novick RP Richmond MH. 1965. Nature and interactions of the genetic elements governing penicillinase synthesis in Staphylococcus aureus . J Bacteriol 90: 467\u2013480. [PubMed]","DOI":"10.1128\/jb.90.2.467-480.1965"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Tipper DJ Strominger JL. 1965. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl- d -alanyl- d -alanine. Proc Natl Acad Sci U S A 54: 1133\u20131141 http:\/\/dx.doi.org\/10.1073\/pnas.54.4.1133. [PubMed]","DOI":"10.1073\/pnas.54.4.1133"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Tomasz A. 1979. The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annu Rev Microbiol 33: 113\u2013137 http:\/\/dx.doi.org\/10.1146\/annurev.mi.33.100179.000553. [PubMed]","DOI":"10.1146\/annurev.mi.33.100179.000553"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Bayles KW. 2000. The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol 8: 274\u2013278 http:\/\/dx.doi.org\/10.1016\/S0966-842X(00)01762-5.","DOI":"10.1016\/S0966-842X(00)01762-5"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Maidhof H Johannsen L Labischinski H Giesbrecht P. 1989. Onset of penicillin-induced bacteriolysis in staphylococci is cell cycle dependent. J Bacteriol 171: 2252\u20132257 http:\/\/dx.doi.org\/10.1128\/jb.171.4.2252-2257.1989. [PubMed]","DOI":"10.1128\/jb.171.4.2252-2257.1989"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Giesbrecht P Kersten T Maidhof H Wecke J. 1998. Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Microbiol Mol Biol Rev 62: 1371\u20131414. [PubMed]","DOI":"10.1128\/MMBR.62.4.1371-1414.1998"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Kirby WM. 1944. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 99: 452\u2013453 http:\/\/dx.doi.org\/10.1126\/science.99.2579.452. [PubMed]","DOI":"10.1126\/science.99.2579.452"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Bondi A Jr Dietz CC. 1945. Penicillin resistant staphylococci. Proc Soc Exp Biol Med 60: 55\u201358 http:\/\/dx.doi.org\/10.3181\/00379727-60-15089. [PubMed]","DOI":"10.3181\/00379727-60-15089"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Berg T Firth N Apisiridej S Hettiaratchi A Leelaporn A Skurray RA. 1998. Complete nucleotide sequence of pSK41: evolution of staphylococcal conjugative multiresistance plasmids. J Bacteriol 180: 4350\u20134359. [PubMed]","DOI":"10.1128\/JB.180.17.4350-4359.1998"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Tenover FC McDougal LK Goering RV Killgore G Projan SJ Patel JB Dunman PM. 2006. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 44: 108\u2013118 http:\/\/dx.doi.org\/10.1128\/JCM.44.1.108-118.2006. [PubMed]","DOI":"10.1128\/JCM.44.1.108-118.2006"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Chambers HF Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7: 629\u2013641 http:\/\/dx.doi.org\/10.1038\/nrmicro2200. [PubMed]","DOI":"10.1038\/nrmicro2200"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Novick RP Roth C. 1968. Plasmid-linked resistance to inorganic salts in Staphylococcus aureus . J Bacteriol 95: 1335\u20131342. [PubMed]","DOI":"10.1128\/jb.95.4.1335-1342.1968"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Jevons MP. 1961. \u201cCelbenin\u201d-resistant staphylococci. BMJ 1: 124\u2013125 http:\/\/dx.doi.org\/10.1136\/bmj.1.5219.124-a.","DOI":"10.1136\/bmj.1.5219.124-a"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Katayama Y Ito T Hiramatsu K. 2000. A new class of genetic element staphylococcus cassette chromosome mec encodes methicillin resistance in Staphylococcus aureus . Antimicrob Agents Chemother 44: 1549\u20131555 http:\/\/dx.doi.org\/10.1128\/AAC.44.6.1549-1555.2000. [PubMed]","DOI":"10.1128\/AAC.44.6.1549-1555.2000"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Ito T Katayama Y Asada K Mori N Tsutsumimoto K Tiensasitorn C Hiramatsu K. 2001. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 45: 1323\u20131336 http:\/\/dx.doi.org\/10.1128\/AAC.45.5.1323-1336.2001. [PubMed]","DOI":"10.1128\/AAC.45.5.1323-1336.2001"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Wu S Piscitelli C de Lencastre H Tomasz A. 1996. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri . Microb Drug Resist 2: 435\u2013441 http:\/\/dx.doi.org\/10.1089\/mdr.1996.2.435. [PubMed]","DOI":"10.1089\/mdr.1996.2.435"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Wu SW de Lencastre H Tomasz A. 2001. Recruitment of the mecA gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus . J Bacteriol 183: 2417\u20132424 http:\/\/dx.doi.org\/10.1128\/JB.183.8.2417-2424.2001. [PubMed]","DOI":"10.1128\/JB.183.8.2417-2424.2001"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Antignac A Tomasz A. 2009. Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene. Antimicrob Agents Chemother 53: 435\u2013441 http:\/\/dx.doi.org\/10.1128\/AAC.01099-08. [PubMed]","DOI":"10.1128\/AAC.01099-08"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Rolo J Worning P Boye Nielsen J Sobral R Bowden R Bouchami O Damborg P Guardabassi L Perreten V Westh H Tomasz A de Lencastre H Miragaia M. 2017. Evidence for the evolutionary steps leading to mecA -mediated \u03b2-lactam resistance in staphylococci. PLoS Genet 13: e1006674 http:\/\/dx.doi.org\/10.1371\/journal.pgen.1006674. [PubMed]","DOI":"10.1371\/journal.pgen.1006674"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Harkins CP Pichon B Doumith M Parkhill J Westh H Tomasz A de Lencastre H Bentley SD Kearns AM Holden MTG. 2017. Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol 18: 130 http:\/\/dx.doi.org\/10.1186\/s13059-017-1252-9. [PubMed]","DOI":"10.1186\/s13059-017-1252-9"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-\u00c1lvarez L Holden MT Lindsay H Webb CR Brown DF Curran MD Walpole E Brooks K Pickard DJ Teale C Parkhill J Bentley SD Edwards GF Girvan EK Kearns AM Pichon B Hill RL Larsen AR Skov RL Peacock SJ Maskell DJ Holmes MA. 2011. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis 11: 595\u2013603 http:\/\/dx.doi.org\/10.1016\/S1473-3099(11)70126-8.","DOI":"10.1016\/S1473-3099(11)70126-8"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Paterson GK Harrison EM Holmes MA. 2014. The emergence of mecC methicillin-resistant Staphylococcus aureus . Trends Microbiol 22: 42\u201347 http:\/\/dx.doi.org\/10.1016\/j.tim.2013.11.003. [PubMed]","DOI":"10.1016\/j.tim.2013.11.003"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","unstructured":"Hiramatsu K Ito T Tsubakishita S Sasaki T Takeuchi F Morimoto Y Katayama Y Matsuo M Kuwahara-Arai K Hishinuma T Baba T. 2013. Genomic basis for methicillin resistance in Staphylococcus aureus . Infect Chemother 45: 117\u2013136 http:\/\/dx.doi.org\/10.3947\/ic.2013.45.2.117. [PubMed]","DOI":"10.3947\/ic.2013.45.2.117"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Boundy S Safo MK Wang L Musayev FN O\u2019Farrell HC Rife JP Archer GL. 2013. Characterization of the Staphylococcus aureus rRNA methyltransferase encoded by orfX the gene containing the staphylococcal chromosome cassette mec (SCC mec ) insertion site. J Biol Chem 288: 132\u2013140 http:\/\/dx.doi.org\/10.1074\/jbc.M112.385138. [PubMed]","DOI":"10.1074\/jbc.M112.385138"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Wisplinghoff H Rosato AE Enright MC Noto M Craig W Archer GL. 2003. Related clones containing SCC mec type IV predominate among clinically significant Staphylococcus epidermidis isolates. Antimicrob Agents Chemother 47: 3574\u20133579 http:\/\/dx.doi.org\/10.1128\/AAC.47.11.3574-3579.2003. [PubMed]","DOI":"10.1128\/AAC.47.11.3574-3579.2003"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Shore AC Coleman DC. 2013. Staphylococcal cassette chromosome mec : recent advances and new insights. Int J Med Microbiol 303: 350\u2013359 http:\/\/dx.doi.org\/10.1016\/j.ijmm.2013.02.002. [PubMed]","DOI":"10.1016\/j.ijmm.2013.02.002"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Ma\u0161la\u0148ov\u00e1 I Do\u0161ka\u0159 J Varga M Kuntov\u00e1 L Mu\u017e\u00edk J Mal\u00fa\u0161kov\u00e1 D R\u016f\u017ei\u010dkov\u00e1 V Pant\u016f\u010dek R. 2013. Bacteriophages of Staphylococcus aureus efficiently package various bacterial genes and mobile genetic elements including SCC mec with different frequencies. Environ Microbiol Rep 5: 66\u201373 http:\/\/dx.doi.org\/10.1111\/j.1758-2229.2012.00378.x. [PubMed]","DOI":"10.1111\/j.1758-2229.2012.00378.x"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Scharn CR Tenover FC Goering RV. 2013. Transduction of staphylococcal cassette chromosome mec elements between strains of Staphylococcus aureus . Antimicrob Agents Chemother 57: 5233\u20135238 http:\/\/dx.doi.org\/10.1128\/AAC.01058-13. [PubMed]","DOI":"10.1128\/AAC.01058-13"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Chlebowicz MA Ma\u0161la\u0148ov\u00e1 I Kuntov\u00e1 L Grundmann H Pant\u016f\u010dek R Do\u0161ka\u0159 J van Dijl JM Buist G. 2014. The staphylococcal cassette chromosome mec type V from Staphylococcus aureus ST398 is packaged into bacteriophage capsids. Int J Med Microbiol 304: 764\u2013774 http:\/\/dx.doi.org\/10.1016\/j.ijmm.2014.05.010. [PubMed]","DOI":"10.1016\/j.ijmm.2014.05.010"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Ray MD Boundy S Archer GL. 2016. Transfer of the methicillin resistance genomic island among staphylococci by conjugation. Mol Microbiol 100: 675\u2013685 http:\/\/dx.doi.org\/10.1111\/mmi.13340. [PubMed]","DOI":"10.1111\/mmi.13340"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"de Lencastre H Oliveira D Tomasz A. 2007. Antibiotic resistant Staphylococcus aureus : a paradigm of adaptive power. Curr Opin Microbiol 10: 428\u2013435 http:\/\/dx.doi.org\/10.1016\/j.mib.2007.08.003. [PubMed]","DOI":"10.1016\/j.mib.2007.08.003"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Kreiswirth B Kornblum J Arbeit RD Eisner W Maslow JN McGeer A Low DE Novick RP. 1993. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus . Science 259: 227\u2013230 http:\/\/dx.doi.org\/10.1126\/science.8093647. [PubMed]","DOI":"10.1126\/science.8093647"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Roberts GA Houston PJ White JH Chen K Stephanou AS Cooper LP Dryden DT Lindsay JA. 2013. Impact of target site distribution for type I restriction enzymes on the evolution of methicillin-resistant Staphylococcus aureus (MRSA) populations. Nucleic Acids Res 41: 7472\u20137484 http:\/\/dx.doi.org\/10.1093\/nar\/gkt535. [PubMed]","DOI":"10.1093\/nar\/gkt535"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). 2009. Classification of staphylococcal cassette chromosome mec (SCC mec ): guidelines for reporting novel SCC mec elements. Antimicrob Agents Chemother 53: 4961\u20134967 http:\/\/dx.doi.org\/10.1128\/AAC.00579-09. [PubMed]","DOI":"10.1128\/AAC.00579-09"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","unstructured":"Bal AM Coombs GW Holden MTG Lindsay JA Nimmo GR Tattevin P Skov RL. 2016. Genomic insights into the emergence and spread of international clones of healthcare- community- and livestock-associated meticillin-resistant Staphylococcus aureus : blurring of the traditional definitions. J Glob Antimicrob Resist 6: 95\u2013101 http:\/\/dx.doi.org\/10.1016\/j.jgar.2016.04.004. [PubMed]","DOI":"10.1016\/j.jgar.2016.04.004"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Tomasz A Nachman S Leaf H. 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 35: 124\u2013129 http:\/\/dx.doi.org\/10.1128\/AAC.35.1.124. [PubMed]","DOI":"10.1128\/AAC.35.1.124"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"de Lencastre H Chung M Westh H. 2000. Archaic strains of methicillin-resistant Staphylococcus aureus : molecular and microbiological properties of isolates from the 1960s in Denmark. Microb Drug Resist 6: 1\u201310 http:\/\/dx.doi.org\/10.1089\/mdr.2000.6.1. [PubMed]","DOI":"10.1089\/mdr.2000.6.1"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"B\u00e6k KT Gr\u00fcndling A Mogensen RG Th\u00f8gersen L Petersen A Paulander W Frees D. 2014. \u03b2-Lactam resistance in methicillin-resistant Staphylococcus aureus USA300 is increased by inactivation of the ClpXP protease. Antimicrob Agents Chemother 58: 4593\u20134603 http:\/\/dx.doi.org\/10.1128\/AAC.02802-14. [PubMed]","DOI":"10.1128\/AAC.02802-14"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Mwangi MM Kim C Chung M Tsai J Vijayadamodar G Benitez M Jarvie TP Du L Tomasz A. 2013. Whole-genome sequencing reveals a link between \u03b2-lactam resistance and synthetases of the alarmone (p)ppGpp in Staphylococcus aureus . Microb Drug Resist 19: 153\u2013159 http:\/\/dx.doi.org\/10.1089\/mdr.2013.0053. [PubMed]","DOI":"10.1089\/mdr.2013.0053"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Kim C Mwangi M Chung M Milheiri\u00e7o C de Lencastre H Tomasz A. 2013. The mechanism of heterogeneous beta-lactam resistance in MRSA: key role of the stringent stress response. PLoS One 8: e82814 http:\/\/dx.doi.org\/10.1371\/journal.pone.0082814. [PubMed]","DOI":"10.1371\/journal.pone.0082814"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Stahlhut SG Alqarzaee AA Jensen C Fisker NS Pereira AR Pinho MG Thomas VC Frees D. 2017. The ClpXP protease is dispensable for degradation of unfolded proteins in Staphylococcus aureus . Sci Rep 7: 11739 http:\/\/dx.doi.org\/10.1038\/s41598-017-12122-y. [PubMed]","DOI":"10.1038\/s41598-017-12122-y"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Parvez MAK Shibata H Nakano T Niimi S Fujii N Arakaki N Higuti T. 2008. No relationship exists between PBP 2a amounts expressed in different MRSA strains obtained clinically and their \u03b2-lactam MIC values. J Med Invest 55: 246\u2013253 http:\/\/dx.doi.org\/10.2152\/jmi.55.246. [PubMed]","DOI":"10.2152\/jmi.55.246"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"Gallagher LA Coughlan S Black NS Lalor P Waters EM Wee B Watson M Downing T Fitzgerald JR Fleming GTA O\u2019Gara JP. 2017. Tandem amplification of the staphylococcal cassette chromosome mec element can drive high-level methicillin resistance in methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 61: e00869-17 http:\/\/dx.doi.org\/10.1128\/AAC.00869-17. [PubMed]","DOI":"10.1128\/AAC.00869-17"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Peacock SJ Paterson GK. 2015. Mechanisms of methicillin resistance in Staphylococcus aureus . Annu Rev Biochem 84: 577\u2013601 http:\/\/dx.doi.org\/10.1146\/annurev-biochem-060614-034516. [PubMed]","DOI":"10.1146\/annurev-biochem-060614-034516"},{"key":"e_1_3_1_50_2","doi-asserted-by":"crossref","unstructured":"Hososaka Y Hanaki H Endo H Suzuki Y Nagasawa Z Otsuka Y Nakae T Sunakawa K. 2007. Characterization of oxacillin-susceptible mecA -positive Staphylococcus aureus : a new type of MRSA. J Infect Chemother 13: 79\u201386 http:\/\/dx.doi.org\/10.1007\/s10156-006-0502-7. [PubMed]","DOI":"10.1007\/s10156-006-0502-7"},{"key":"e_1_3_1_51_2","doi-asserted-by":"crossref","unstructured":"Murakami K Tomasz A. 1989. Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus . J Bacteriol 171: 874\u2013879 http:\/\/dx.doi.org\/10.1128\/jb.171.2.874-879.1989. [PubMed]","DOI":"10.1128\/jb.171.2.874-879.1989"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","unstructured":"Berger-B\u00e4chi B Rohrer S. 2002. Factors influencing methicillin resistance in staphylococci. Arch Microbiol 178: 165\u2013171 http:\/\/dx.doi.org\/10.1007\/s00203-002-0436-0. [PubMed]","DOI":"10.1007\/s00203-002-0436-0"},{"key":"e_1_3_1_53_2","doi-asserted-by":"crossref","unstructured":"Tan CM Therien AG Lu J Lee SH Caron A Gill CJ Lebeau-Jacob C Benton-Perdomo L Monteiro JM Pereira PM. 2012. Restoring methicillin-resistant Staphylococcus aureus susceptibility to \u03b2-lactam antibiotics. Sci Transl Med 4: 126ra35.","DOI":"10.1126\/scitranslmed.3003592"},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","unstructured":"Pinho MG de Lencastre H Tomasz A. 2001. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc Natl Acad Sci U S A 98: 10886\u201310891 http:\/\/dx.doi.org\/10.1073\/pnas.191260798. [PubMed]","DOI":"10.1073\/pnas.191260798"},{"key":"e_1_3_1_55_2","doi-asserted-by":"crossref","unstructured":"Campbell J Singh AK Santa Maria JP Jr Kim Y Brown S Swoboda JG Mylonakis E Wilkinson BJ Walker S. 2011. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus . ACS Chem Biol 6: 106\u2013116 http:\/\/dx.doi.org\/10.1021\/cb100269f. [PubMed]","DOI":"10.1021\/cb100269f"},{"key":"e_1_3_1_56_2","doi-asserted-by":"crossref","unstructured":"Ejim L Farha MA Falconer SB Wildenhain J Coombes BK Tyers M Brown ED Wright GD. 2011. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol 7: 348\u2013350 http:\/\/dx.doi.org\/10.1038\/nchembio.559. [PubMed]","DOI":"10.1038\/nchembio.559"},{"key":"e_1_3_1_57_2","doi-asserted-by":"crossref","unstructured":"Roemer T Schneider T Pinho MG. 2013. Auxiliary factors: a chink in the armor of MRSA resistance to \u03b2-lactam antibiotics. Curr Opin Microbiol 16: 538\u2013548 http:\/\/dx.doi.org\/10.1016\/j.mib.2013.06.012. [PubMed]","DOI":"10.1016\/j.mib.2013.06.012"},{"key":"e_1_3_1_58_2","doi-asserted-by":"crossref","unstructured":"Drawz SM Bonomo RA. 2010. Three decades of \u03b2-lactamase inhibitors. Clin Microbiol Rev 23: 160\u2013201 http:\/\/dx.doi.org\/10.1128\/CMR.00037-09. [PubMed]","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_1_59_2","doi-asserted-by":"crossref","unstructured":"Saravolatz LD Stein GE Johnson LB. 2011. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus . Clin Infect Dis 52: 1156\u20131163 http:\/\/dx.doi.org\/10.1093\/cid\/cir147. [PubMed]","DOI":"10.1093\/cid\/cir147"},{"key":"e_1_3_1_60_2","doi-asserted-by":"crossref","unstructured":"Lim D Strynadka NC. 2002. Structural basis for the \u03b2 lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus . Nat Struct Biol 9: 870\u2013876.","DOI":"10.1038\/nsb858"},{"key":"e_1_3_1_61_2","doi-asserted-by":"crossref","unstructured":"Otero LH Rojas-Altuve A Llarrull LI Carrasco-L\u00f3pez C Kumarasiri M Lastochkin E Fishovitz J Dawley M Hesek D Lee M Johnson JW Fisher JF Chang M Mobashery S Hermoso JA. 2013. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci U S A 110: 16808\u201316813 http:\/\/dx.doi.org\/10.1073\/pnas.1300118110. [PubMed]","DOI":"10.1073\/pnas.1300118110"},{"key":"e_1_3_1_62_2","doi-asserted-by":"crossref","unstructured":"Harrison EM Ba X Blane B Ellington MJ Loeffler A Hill RL Holmes MA Peacock SJ. 2016. PBP2a substitutions linked to ceftaroline resistance in MRSA isolates from the UK. J Antimicrob Chemother 71: 268\u2013269 http:\/\/dx.doi.org\/10.1093\/jac\/dkv317. [PubMed]","DOI":"10.1093\/jac\/dkv317"},{"key":"e_1_3_1_63_2","doi-asserted-by":"crossref","unstructured":"Sanchez EH Mendes RE Sader HS Allison GM. 2016. In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis. J Antimicrob Chemother 71: 1736\u20131738 http:\/\/dx.doi.org\/10.1093\/jac\/dkw001. [PubMed]","DOI":"10.1093\/jac\/dkw001"},{"key":"e_1_3_1_64_2","doi-asserted-by":"crossref","unstructured":"Levine DP. 2006. Vancomycin: a history. Clin Infect Dis 42 (Suppl 1) : S5\u2013S12 http:\/\/dx.doi.org\/10.1086\/491709. [PubMed]","DOI":"10.1086\/491709"},{"key":"e_1_3_1_65_2","doi-asserted-by":"crossref","unstructured":"Barna JC Williams DH. 1984. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 38: 339\u2013357 http:\/\/dx.doi.org\/10.1146\/annurev.mi.38.100184.002011. [PubMed]","DOI":"10.1146\/annurev.mi.38.100184.002011"},{"key":"e_1_3_1_66_2","doi-asserted-by":"crossref","unstructured":"Arthur M Reynolds P Courvalin P. 1996. Glycopeptide resistance in enterococci. Trends Microbiol 4: 401\u2013407 http:\/\/dx.doi.org\/10.1016\/0966-842X(96)10063-9.","DOI":"10.1016\/0966-842X(96)10063-9"},{"key":"e_1_3_1_67_2","doi-asserted-by":"crossref","unstructured":"Chang S Sievert DM Hageman JC Boulton ML Tenover FC Downes FP Shah S Rudrik JT Pupp GR Brown WJ Cardo D Fridkin SK Vancomycin-Resistant Staphylococcus aureus Investigative Team. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348: 1342\u20131347 http:\/\/dx.doi.org\/10.1056\/NEJMoa025025. [PubMed]","DOI":"10.1056\/NEJMoa025025"},{"key":"e_1_3_1_68_2","doi-asserted-by":"crossref","unstructured":"Weigel LM Clewell DB Gill SR Clark NC McDougal LK Flannagan SE Kolonay JF Shetty J Killgore GE Tenover FC. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus . Science 302: 1569\u20131571 http:\/\/dx.doi.org\/10.1126\/science.1090956. [PubMed]","DOI":"10.1126\/science.1090956"},{"key":"e_1_3_1_69_2","doi-asserted-by":"crossref","unstructured":"Gardete S Tomasz A. 2014. Mechanisms of vancomycin resistance in Staphylococcus aureus . J Clin Invest 124: 2836\u20132840 http:\/\/dx.doi.org\/10.1172\/JCI68834. [PubMed]","DOI":"10.1172\/JCI68834"},{"key":"e_1_3_1_70_2","doi-asserted-by":"crossref","unstructured":"Zhu W Murray PR Huskins WC Jernigan JA McDonald LC Clark NC Anderson KF McDougal LK Hageman JC Olsen-Rasmussen M Frace M Alangaden GJ Chenoweth C Zervos MJ Robinson-Dunn B Schreckenberger PC Reller LB Rudrik JT Patel JB. 2010. Dissemination of an Enterococcus Inc18-like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 54: 4314\u20134320 http:\/\/dx.doi.org\/10.1128\/AAC.00185-10. [PubMed]","DOI":"10.1128\/AAC.00185-10"},{"key":"e_1_3_1_71_2","doi-asserted-by":"crossref","unstructured":"Severin A Wu SW Tabei K Tomasz A. 2004. Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the enterococcal vanA gene complex. Antimicrob Agents Chemother 48: 4566\u20134573 http:\/\/dx.doi.org\/10.1128\/AAC.48.12.4566-4573.2004. [PubMed]","DOI":"10.1128\/AAC.48.12.4566-4573.2004"},{"key":"e_1_3_1_72_2","doi-asserted-by":"crossref","unstructured":"Ortwine JK Werth BJ Sakoulas G Rybak MJ. 2013. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the \u201cseesaw effect\u201d: taking advantage of the back door left open? Drug Resist Updat 16: 73\u201379 http:\/\/dx.doi.org\/10.1016\/j.drup.2013.10.002. [PubMed]","DOI":"10.1016\/j.drup.2013.10.002"},{"key":"e_1_3_1_73_2","doi-asserted-by":"crossref","unstructured":"Lodise TP Graves J Evans A Graffunder E Helmecke M Lomaestro BM Stellrecht K. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315\u20133320 http:\/\/dx.doi.org\/10.1128\/AAC.00113-08. [PubMed]","DOI":"10.1128\/AAC.00113-08"},{"key":"e_1_3_1_74_2","doi-asserted-by":"crossref","unstructured":"Wi YM Kim JM Joo E-J Ha YE Kang C-I Ko KS Chung DR Song J-H Peck KR. 2012. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 40: 108\u2013113 http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2012.04.003. [PubMed]","DOI":"10.1016\/j.ijantimicag.2012.04.003"},{"key":"e_1_3_1_75_2","doi-asserted-by":"crossref","unstructured":"Woods CJ Chowdhury A Patel VM Shorr AF. 2012. Impact of vancomycin minimum inhibitory concentration on mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 33: 1246\u20131249 http:\/\/dx.doi.org\/10.1086\/668433. [PubMed]","DOI":"10.1086\/668433"},{"key":"e_1_3_1_76_2","doi-asserted-by":"crossref","unstructured":"Wang J-L Lai C-H Lin H-H Chen W-F Shih Y-C Hung C-H. 2013. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients. Int J Antimicrob Agents 42: 390\u2013394 http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2013.07.010. [PubMed]","DOI":"10.1016\/j.ijantimicag.2013.07.010"},{"key":"e_1_3_1_77_2","doi-asserted-by":"crossref","unstructured":"Cameron DR Lin Y-H Trouillet-Assant S Tafani V Kostoulias X Mouhtouris E Skinner N Visvanathan K Baines SL Howden B Monk IR Laurent F Stinear TP Howden BP Peleg AY. 2017. Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors. Clin Microbiol Infect 23: 767\u2013773 http:\/\/dx.doi.org\/10.1016\/j.cmi.2017.03.027. [PubMed]","DOI":"10.1016\/j.cmi.2017.03.027"},{"key":"e_1_3_1_78_2","doi-asserted-by":"crossref","unstructured":"Gould IM Cauda R Esposito S Gudiol F Mazzei T Garau J. 2011. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents 37: 202\u2013209 http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2010.10.030. [PubMed]","DOI":"10.1016\/j.ijantimicag.2010.10.030"},{"key":"e_1_3_1_79_2","doi-asserted-by":"crossref","unstructured":"Daum RS Gupta S Sabbagh R Milewski WM. 1992. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 166: 1066\u20131072 http:\/\/dx.doi.org\/10.1093\/infdis\/166.5.1066. [PubMed]","DOI":"10.1093\/infdis\/166.5.1066"},{"key":"e_1_3_1_80_2","doi-asserted-by":"crossref","unstructured":"Hanaki H Kuwahara-Arai K Boyle-Vavra S Daum RS Labischinski H Hiramatsu K. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 42: 199\u2013209 http:\/\/dx.doi.org\/10.1093\/jac\/42.2.199. [PubMed]","DOI":"10.1093\/jac\/42.2.199"},{"key":"e_1_3_1_81_2","doi-asserted-by":"crossref","unstructured":"Sieradzki K Tomasz A. 2003. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus . J Bacteriol 185: 7103\u20137110 http:\/\/dx.doi.org\/10.1128\/JB.185.24.7103-7110.2003. [PubMed]","DOI":"10.1128\/JB.185.24.7103-7110.2003"},{"key":"e_1_3_1_82_2","doi-asserted-by":"crossref","unstructured":"Cui L Murakami H Kuwahara-Arai K Hanaki H Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 44: 2276\u20132285 http:\/\/dx.doi.org\/10.1128\/AAC.44.9.2276-2285.2000. [PubMed]","DOI":"10.1128\/AAC.44.9.2276-2285.2000"},{"key":"e_1_3_1_83_2","doi-asserted-by":"crossref","unstructured":"Cui L Ma X Sato K Okuma K Tenover FC Mamizuka EM Gemmell CG Kim M-N Ploy M-C El-Solh N Ferraz V Hiramatsu K. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus . J Clin Microbiol 41: 5\u201314 http:\/\/dx.doi.org\/10.1128\/JCM.41.1.5-14.2003. [PubMed]","DOI":"10.1128\/JCM.41.1.5-14.2003"},{"key":"e_1_3_1_84_2","doi-asserted-by":"crossref","unstructured":"Cui L Iwamoto A Lian J-Q Neoh HM Maruyama T Horikawa Y Hiramatsu K. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus . Antimicrob Agents Chemother 50: 428\u2013438 http:\/\/dx.doi.org\/10.1128\/AAC.50.2.428-438.2006. [PubMed]","DOI":"10.1128\/AAC.50.2.428-438.2006"},{"key":"e_1_3_1_85_2","doi-asserted-by":"crossref","unstructured":"Howden BP Johnson PD Ward PB Stinear TP Davies JK. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50: 3039\u20133047 http:\/\/dx.doi.org\/10.1128\/AAC.00422-06. [PubMed]","DOI":"10.1128\/AAC.00422-06"},{"key":"e_1_3_1_86_2","doi-asserted-by":"crossref","unstructured":"Boyle-Vavra S Carey RB Daum RS. 2001. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother 48: 617\u2013625 http:\/\/dx.doi.org\/10.1093\/jac\/48.5.617. [PubMed]","DOI":"10.1093\/jac\/48.5.617"},{"key":"e_1_3_1_87_2","doi-asserted-by":"crossref","unstructured":"Boyle-Vavra S Labischinski H Ebert CC Ehlert K Daum RS. 2001. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother 45: 280\u2013287 http:\/\/dx.doi.org\/10.1128\/AAC.45.1.280-287.2001. [PubMed]","DOI":"10.1128\/AAC.45.1.280-287.2001"},{"key":"e_1_3_1_88_2","doi-asserted-by":"crossref","unstructured":"Koehl JL Muthaiyan A Jayaswal RK Ehlert K Labischinski H Wilkinson BJ. 2004. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus . Antimicrob Agents Chemother 48: 3749\u20133757 http:\/\/dx.doi.org\/10.1128\/AAC.48.10.3749-3757.2004. [PubMed]","DOI":"10.1128\/AAC.48.10.3749-3757.2004"},{"key":"e_1_3_1_89_2","doi-asserted-by":"crossref","unstructured":"Meehl M Herbert S G\u00f6tz F Cheung A. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus . Antimicrob Agents Chemother 51: 2679\u20132689 http:\/\/dx.doi.org\/10.1128\/AAC.00209-07. [PubMed]","DOI":"10.1128\/AAC.00209-07"},{"key":"e_1_3_1_90_2","doi-asserted-by":"crossref","unstructured":"Hiramatsu K Kayayama Y Matsuo M Aiba Y Saito M Hishinuma T Iwamoto A. 2014. Vancomycin-intermediate resistance in Staphylococcus aureus . J Glob Antimicrob Resist 2: 213\u2013224 http:\/\/dx.doi.org\/10.1016\/j.jgar.2014.04.006. [PubMed]","DOI":"10.1016\/j.jgar.2014.04.006"},{"key":"e_1_3_1_91_2","unstructured":"McGuinness WA Malachowa N DeLeo FR. 2017. Vancomycin resistance in Staphylococcus aureus . Yale J Biol Med 90: 269\u2013281. [PubMed]"},{"key":"e_1_3_1_92_2","doi-asserted-by":"crossref","unstructured":"Vidaillac C Gardete S Tewhey R Sakoulas G Kaatz GW Rose WE Tomasz A Rybak MJ. 2013. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus . J Infect Dis 208: 67\u201374 http:\/\/dx.doi.org\/10.1093\/infdis\/jit127. [PubMed]","DOI":"10.1093\/infdis\/jit127"},{"key":"e_1_3_1_93_2","doi-asserted-by":"crossref","unstructured":"Hu Q Peng H Rao X. 2016. Molecular events for promotion of vancomycin resistance in vancomycin intermediate Staphylococcus aureus . Front Microbiol 7: 1601 http:\/\/dx.doi.org\/10.3389\/fmicb.2016.01601. [PubMed]","DOI":"10.3389\/fmicb.2016.01601"},{"key":"e_1_3_1_94_2","doi-asserted-by":"crossref","unstructured":"Katayama Y Sekine M Hishinuma T Aiba Y Hiramatsu K. 2016. Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus phenotype of strain Mu50 in vancomycin-susceptible S. aureus . Antimicrob Agents Chemother 60: 3730\u20133742 http:\/\/dx.doi.org\/10.1128\/AAC.00420-16. [PubMed]","DOI":"10.1128\/AAC.00420-16"},{"key":"e_1_3_1_95_2","doi-asserted-by":"crossref","unstructured":"Mwangi MM Wu SW Zhou Y Sieradzki K de Lencastre H Richardson P Bruce D Rubin E Myers E Siggia ED Tomasz A. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104: 9451\u20139456 http:\/\/dx.doi.org\/10.1073\/pnas.0609839104. [PubMed]","DOI":"10.1073\/pnas.0609839104"},{"key":"e_1_3_1_96_2","doi-asserted-by":"crossref","unstructured":"Howden BP McEvoy CR Allen DL Chua K Gao W Harrison PF Bell J Coombs G Bennett-Wood V Porter JL Robins-Browne R Davies JK Seemann T Stinear TP. 2011. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 7: e1002359 http:\/\/dx.doi.org\/10.1371\/journal.ppat.1002359. [PubMed]","DOI":"10.1371\/journal.ppat.1002359"},{"key":"e_1_3_1_97_2","doi-asserted-by":"crossref","unstructured":"Gardete S Kim C Hartmann BM Mwangi M Roux CM Dunman PM Chambers HF Tomasz A. 2012. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog 8: e1002505. [PubMed]","DOI":"10.1371\/journal.ppat.1002505"},{"key":"e_1_3_1_98_2","doi-asserted-by":"crossref","unstructured":"Matsuo M Cui L Kim J Hiramatsu K. 2013. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrob Agents Chemother 57: 5843\u20135853 http:\/\/dx.doi.org\/10.1128\/AAC.00425-13. [PubMed]","DOI":"10.1128\/AAC.00425-13"},{"key":"e_1_3_1_99_2","doi-asserted-by":"crossref","unstructured":"Roch M Clair P Renzoni A Reverdy M-E Dauwalder O Bes M Martra A Freydi\u00e8re A-M Laurent F Reix P Dumitrescu O Vandenesch F. 2014. Exposure of Staphylococcus aureus to subinhibitory concentrations of \u03b2-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus . Antimicrob Agents Chemother 58: 5306\u20135314 http:\/\/dx.doi.org\/10.1128\/AAC.02574-14. [PubMed]","DOI":"10.1128\/AAC.02574-14"},{"key":"e_1_3_1_100_2","doi-asserted-by":"crossref","unstructured":"Katayama Y Murakami-Kuroda H Cui L Hiramatsu K. 2009. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob Agents Chemother 53: 3190\u20133196 http:\/\/dx.doi.org\/10.1128\/AAC.00834-08. [PubMed]","DOI":"10.1128\/AAC.00834-08"},{"key":"e_1_3_1_101_2","doi-asserted-by":"crossref","unstructured":"Renzoni A Kelley WL Barras C Monod A Huggler E Fran\u00e7ois P Schrenzel J Studer R Vaudaux P Lew DP. 2009. Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus . Antimicrob Agents Chemother 53: 903\u2013911 http:\/\/dx.doi.org\/10.1128\/AAC.01287-08. [PubMed]","DOI":"10.1128\/AAC.01287-08"},{"key":"e_1_3_1_102_2","doi-asserted-by":"crossref","unstructured":"Donegan NP Marvin JS Cheung AL. 2014. Role of adaptor TrfA and ClpPC in controlling levels of SsrA-tagged proteins and antitoxins in Staphylococcus aureus . J Bacteriol 196: 4140\u20134151 http:\/\/dx.doi.org\/10.1128\/JB.02222-14. [PubMed]","DOI":"10.1128\/JB.02222-14"},{"key":"e_1_3_1_103_2","doi-asserted-by":"crossref","unstructured":"Frees D Chastanet A Qazi S S\u00f8rensen K Hill P Msadek T Ingmer H. 2004. Clp ATPases are required for stress tolerance intracellular replication and biofilm formation in Staphylococcus aureus . Mol Microbiol 54: 1445\u20131462 http:\/\/dx.doi.org\/10.1111\/j.1365-2958.2004.04368.x. [PubMed]","DOI":"10.1111\/j.1365-2958.2004.04368.x"},{"key":"e_1_3_1_104_2","doi-asserted-by":"crossref","unstructured":"Howden BP Smith DJ Mansell A Johnson PD Ward PB Stinear TP Davies JK. 2008. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol 8: 39 http:\/\/dx.doi.org\/10.1186\/1471-2180-8-39. [PubMed]","DOI":"10.1186\/1471-2180-8-39"},{"key":"e_1_3_1_105_2","doi-asserted-by":"crossref","unstructured":"Saito M Katayama Y Hishinuma T Iwamoto A Aiba Y Kuwahara-Arai K Cui L Matsuo M Aritaka N Hiramatsu K. 2014. \u201cSlow VISA \u201d a novel phenotype of vancomycin resistance found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. Antimicrob Agents Chemother 58: 5024\u20135035 http:\/\/dx.doi.org\/10.1128\/AAC.02470-13. [PubMed]","DOI":"10.1128\/AAC.02470-13"},{"key":"e_1_3_1_106_2","doi-asserted-by":"crossref","unstructured":"Matsuo M Hishinuma T Katayama Y Hiramatsu K. 2015. A mutation of RNA polymerase \u03b2&prime; subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into \u201cslow VISA\u201d. Antimicrob Agents Chemother 59: 4215\u20134225 http:\/\/dx.doi.org\/10.1128\/AAC.00135-15. [PubMed]","DOI":"10.1128\/AAC.00135-15"},{"key":"e_1_3_1_107_2","doi-asserted-by":"crossref","unstructured":"Geiger T K\u00e4stle B Gratani FL Goerke C Wolz C. 2014. Two small (p)ppGpp synthases in Staphylococcus aureus mediate tolerance against cell envelope stress conditions. J Bacteriol 196: 894\u2013902 http:\/\/dx.doi.org\/10.1128\/JB.01201-13. [PubMed]","DOI":"10.1128\/JB.01201-13"},{"key":"e_1_3_1_108_2","doi-asserted-by":"crossref","unstructured":"Katayama Y Azechi T Miyazaki M Takata T Sekine M Matsui H Hanaki H Yahara K Sasano H Asakura K Takaku T Ochiai T Komatsu N Chambers HF. 2017. Prevalence of slow-growth vancomycin nonsusceptibility in methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 61: e00452-17 http:\/\/dx.doi.org\/10.1128\/AAC.00452-17. [PubMed]","DOI":"10.1128\/AAC.00452-17"},{"key":"e_1_3_1_109_2","doi-asserted-by":"crossref","unstructured":"Haaber J Friberg C McCreary M Lin R Cohen SN Ingmer H. 2015. Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure. MBio 6: e02268-14 http:\/\/dx.doi.org\/10.1128\/mBio.02268-14. [PubMed]","DOI":"10.1128\/mBio.02268-14"},{"key":"e_1_3_1_110_2","doi-asserted-by":"crossref","unstructured":"Cornaglia G Rossolini GM. 2009. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect 15: 218\u2013223 http:\/\/dx.doi.org\/10.1111\/j.1469-0691.2009.02740.x. [PubMed]","DOI":"10.1111\/j.1469-0691.2009.02740.x"},{"key":"e_1_3_1_111_2","doi-asserted-by":"crossref","unstructured":"Van Bambeke F. 2015. Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review. Drugs 75: 2073\u20132095 http:\/\/dx.doi.org\/10.1007\/s40265-015-0505-8. [PubMed]","DOI":"10.1007\/s40265-015-0505-8"},{"key":"e_1_3_1_112_2","doi-asserted-by":"crossref","unstructured":"Higgins DL Chang R Debabov DV Leung J Wu T Krause KM Sandvik E Hubbard JM Kaniga K Schmidt DE Jr Gao Q Cass RT Karr DE Benton BM Humphrey PP. 2005. Telavancin a multifunctional lipoglycopeptide disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 49: 1127\u20131134 http:\/\/dx.doi.org\/10.1128\/AAC.49.3.1127-1134.2005. [PubMed]","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_1_113_2","doi-asserted-by":"crossref","unstructured":"Karlowsky JA Nichol K Zhanel GG. 2015. Telavancin: mechanisms of action in vitro activity and mechanisms of resistance. Clin Infect Dis 61 (Suppl 2) : S58\u2013S68 http:\/\/dx.doi.org\/10.1093\/cid\/civ534. [PubMed]","DOI":"10.1093\/cid\/civ534"},{"key":"e_1_3_1_114_2","doi-asserted-by":"crossref","unstructured":"Citron DM Tyrrell KL Goldstein EJ. 2014. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis 79: 438\u2013440 http:\/\/dx.doi.org\/10.1016\/j.diagmicrobio.2014.05.014. [PubMed]","DOI":"10.1016\/j.diagmicrobio.2014.05.014"},{"key":"e_1_3_1_115_2","doi-asserted-by":"crossref","unstructured":"Smith JR Roberts KD Rybak MJ. 2015. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther 4: 245\u2013258 http:\/\/dx.doi.org\/10.1007\/s40121-015-0077-7. [PubMed]","DOI":"10.1007\/s40121-015-0077-7"},{"key":"e_1_3_1_116_2","doi-asserted-by":"crossref","unstructured":"McKay GA Beaulieu S Arhin FF Belley A Sarmiento I Parr T Jr Moeck G. 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus Enterococcus faecalis and Enterococcus faecium . J Antimicrob Chemother 63: 1191\u20131199 http:\/\/dx.doi.org\/10.1093\/jac\/dkp126. [PubMed]","DOI":"10.1093\/jac\/dkp126"},{"key":"e_1_3_1_117_2","doi-asserted-by":"crossref","unstructured":"Kim SJ Cegelski L Stueber D Singh M Dietrich E Tanaka KS Parr TR Jr Far AR Schaefer J. 2008. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus . J Mol Biol 377: 281\u2013293 http:\/\/dx.doi.org\/10.1016\/j.jmb.2008.01.031. [PubMed]","DOI":"10.1016\/j.jmb.2008.01.031"},{"key":"e_1_3_1_118_2","doi-asserted-by":"crossref","unstructured":"Zhanel GG Trapp S Gin AS DeCorby M Lagac\u00e9-Wiens PR Rubinstein E Hoban DJ Karlowsky JA. 2008. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 6: 67\u201381 http:\/\/dx.doi.org\/10.1586\/14787210.6.1.67. [PubMed]","DOI":"10.1586\/14787210.6.1.67"},{"key":"e_1_3_1_119_2","doi-asserted-by":"crossref","unstructured":"Bal AM Garau J Gould IM Liao CH Mazzei T Nimmo GR Soriano A Stefani S Tenover FC. 2013. Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: end of an era? J Glob Antimicrob Resist 1: 23\u201330 http:\/\/dx.doi.org\/10.1016\/j.jgar.2013.01.002. [PubMed]","DOI":"10.1016\/j.jgar.2013.01.002"},{"key":"e_1_3_1_120_2","doi-asserted-by":"crossref","unstructured":"Kosowska-Shick K Clark C Pankuch GA McGhee P Dewasse B Beachel L Appelbaum PC. 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 53: 4217\u20134224 http:\/\/dx.doi.org\/10.1128\/AAC.00742-09. [PubMed]","DOI":"10.1128\/AAC.00742-09"},{"key":"e_1_3_1_121_2","doi-asserted-by":"crossref","unstructured":"Goldstein BP Draghi DC Sheehan DJ Hogan P Sahm DF. 2007. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 51: 1150\u20131154 http:\/\/dx.doi.org\/10.1128\/AAC.00620-06. [PubMed]","DOI":"10.1128\/AAC.00620-06"},{"key":"e_1_3_1_122_2","doi-asserted-by":"crossref","unstructured":"Werth BJ Jain R Hahn A Cummings L Weaver T Waalkes A Sengupta D Salipante SJ Rakita RM Butler-Wu SM. 2017. Emergence of dalbavancin non-susceptible vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect 24: 429.e1\u2013429.e5 http:\/\/dx.doi.org\/10.1016\/j.cmi.2017.07.028. [PubMed]","DOI":"10.1016\/j.cmi.2017.07.028"},{"key":"e_1_3_1_123_2","doi-asserted-by":"crossref","unstructured":"Yoo JI Kim JW Kang GS Kim HS Yoo JS Lee YS. 2013. Prevalence of amino acid changes in the yvqF vraSR graSR and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus . J Microbiol 51: 160\u2013165 http:\/\/dx.doi.org\/10.1007\/s12275-013-3088-7. [PubMed]","DOI":"10.1007\/s12275-013-3088-7"},{"key":"e_1_3_1_124_2","doi-asserted-by":"crossref","unstructured":"Falagas ME Giannopoulou KP Kokolakis GN Rafailidis PI. 2008. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 46: 1069\u20131077 http:\/\/dx.doi.org\/10.1086\/527442. [PubMed]","DOI":"10.1086\/527442"},{"key":"e_1_3_1_125_2","doi-asserted-by":"crossref","unstructured":"Falagas ME Roussos N Gkegkes ID Rafailidis PI Karageorgopoulos DE. 2009. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological animal and clinical studies. Expert Opin Investig Drugs 18: 921\u2013944 http:\/\/dx.doi.org\/10.1517\/13543780902967624. [PubMed]","DOI":"10.1517\/13543780902967624"},{"key":"e_1_3_1_126_2","doi-asserted-by":"crossref","unstructured":"Michalopoulos AS Livaditis IG Gougoutas V. 2011. The revival of fosfomycin. Int J Infect Dis 15: e732\u2013e739 http:\/\/dx.doi.org\/10.1016\/j.ijid.2011.07.007. [PubMed]","DOI":"10.1016\/j.ijid.2011.07.007"},{"key":"e_1_3_1_127_2","doi-asserted-by":"crossref","unstructured":"Roberts AA Sharma SV Strankman AW Duran SR Rawat M Hamilton CJ. 2013. Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus . Biochem J 451: 69\u201379 http:\/\/dx.doi.org\/10.1042\/BJ20121541. [PubMed]","DOI":"10.1042\/BJ20121541"},{"key":"e_1_3_1_128_2","doi-asserted-by":"crossref","unstructured":"Fu Z Ma Y Chen C Guo Y Hu F Liu Y Xu X Wang M. 2016. Prevalence of fosfomycin resistance and mutations in murA glpT and uhpT in methicillin-resistant Staphylococcus aureus strains isolated from blood and cerebrospinal fluid samples. Front Microbiol 6: 1544 http:\/\/dx.doi.org\/10.3389\/fmicb.2015.01544. [PubMed]","DOI":"10.3389\/fmicb.2015.01544"},{"key":"e_1_3_1_129_2","doi-asserted-by":"crossref","unstructured":"Casta\u00f1eda-Garc\u00eda A Bl\u00e1zquez J Rodr\u00edguez-Rojas A. 2013. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics (Basel) 2: 217\u2013236 http:\/\/dx.doi.org\/10.3390\/antibiotics2020217. [PubMed]","DOI":"10.3390\/antibiotics2020217"},{"key":"e_1_3_1_130_2","doi-asserted-by":"crossref","unstructured":"Takahata S Ida T Hiraishi T Sakakibara S Maebashi K Terada S Muratani T Matsumoto T Nakahama C Tomono K. 2010. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli . Int J Antimicrob Agents 35: 333\u2013337 http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2009.11.011. [PubMed]","DOI":"10.1016\/j.ijantimicag.2009.11.011"},{"key":"e_1_3_1_131_2","doi-asserted-by":"crossref","unstructured":"Miller WR Bayer AS Arias CA. 2016. Mechanism of action and resistance to daptomycin in Staphylococcus aureus and enterococci. Cold Spring Harb Perspect Med 6: a026997 http:\/\/dx.doi.org\/10.1101\/cshperspect.a026997. [PubMed]","DOI":"10.1101\/cshperspect.a026997"},{"key":"e_1_3_1_132_2","doi-asserted-by":"crossref","unstructured":"Boucher H Miller LG Razonable RR. 2010. Serious infections caused by methicillin-resistant Staphylococcus aureus . Clin Infect Dis 51 (Suppl 2) : S183\u2013S197 http:\/\/dx.doi.org\/10.1086\/653519. [PubMed]","DOI":"10.1086\/653519"},{"key":"e_1_3_1_133_2","doi-asserted-by":"crossref","unstructured":"Mascio CT Alder JD Silverman JA. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51: 4255\u20134260 http:\/\/dx.doi.org\/10.1128\/AAC.00824-07. [PubMed]","DOI":"10.1128\/AAC.00824-07"},{"key":"e_1_3_1_134_2","doi-asserted-by":"crossref","unstructured":"Sader HS Farrell DJ Flamm RK Jones RN. 2014. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). Int J Antimicrob Agents 43: 465\u2013469 http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2014.01.018. [PubMed]","DOI":"10.1016\/j.ijantimicag.2014.01.018"},{"key":"e_1_3_1_135_2","doi-asserted-by":"crossref","unstructured":"Peleg AY Miyakis S Ward DV Earl AM Rubio A Cameron DR Pillai S Moellering RC Jr Eliopoulos GM. 2012. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus . PLoS One 7: e28316 http:\/\/dx.doi.org\/10.1371\/journal.pone.0028316. [PubMed]","DOI":"10.1371\/journal.pone.0028316"},{"key":"e_1_3_1_136_2","doi-asserted-by":"crossref","unstructured":"Bayer AS Mishra NN Sakoulas G Nonejuie P Nast CC Pogliano J Chen K-T Ellison SN Yeaman MR Yang S-J. 2014. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 58: 7462\u20137467 http:\/\/dx.doi.org\/10.1128\/AAC.03422-14. [PubMed]","DOI":"10.1128\/AAC.03422-14"},{"key":"e_1_3_1_137_2","doi-asserted-by":"crossref","unstructured":"Bayer AS Mishra NN Chen L Kreiswirth BN Rubio A Yang S-J. 2015. Frequency and distribution of single-nucleotide polymorphisms within mprF in methicillin-resistant Staphylococcus aureus clinical isolates and their role in cross-resistance to daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 59: 4930\u20134937 http:\/\/dx.doi.org\/10.1128\/AAC.00970-15. [PubMed]","DOI":"10.1128\/AAC.00970-15"},{"key":"e_1_3_1_138_2","doi-asserted-by":"crossref","unstructured":"Ernst CM Staubitz P Mishra NN Yang S-J Hornig G Kalbacher H Bayer AS Kraus D Peschel A. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5: e1000660 http:\/\/dx.doi.org\/10.1371\/journal.ppat.1000660. [PubMed]","DOI":"10.1371\/journal.ppat.1000660"},{"key":"e_1_3_1_139_2","doi-asserted-by":"crossref","unstructured":"Kang K-M Mishra NN Park KT Lee G-Y Park YH Bayer AS Yang S-J. 2017. Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates. J Microbiol 55: 153\u2013159 http:\/\/dx.doi.org\/10.1007\/s12275-017-6509-1. [PubMed]","DOI":"10.1007\/s12275-017-6509-1"},{"key":"e_1_3_1_140_2","doi-asserted-by":"crossref","unstructured":"Bayer AS Mishra NN Cheung AL Rubio A Yang S-J. 2016. Dysregulation of mprF and dltABCD expression among daptomycin-non-susceptible MRSA clinical isolates. J Antimicrob Chemother 71: 2100\u20132104 http:\/\/dx.doi.org\/10.1093\/jac\/dkw142. [PubMed]","DOI":"10.1093\/jac\/dkw142"},{"key":"e_1_3_1_141_2","doi-asserted-by":"crossref","unstructured":"Friedman L Alder JD Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus . Antimicrob Agents Chemother 50: 2137\u20132145 http:\/\/dx.doi.org\/10.1128\/AAC.00039-06. [PubMed]","DOI":"10.1128\/AAC.00039-06"},{"key":"e_1_3_1_142_2","doi-asserted-by":"crossref","unstructured":"Cui L Isii T Fukuda M Ochiai T Neoh HM Camargo IL Watanabe Y Shoji M Hishinuma T Hiramatsu K. 2010. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus . Antimicrob Agents Chemother 54: 5222\u20135233 http:\/\/dx.doi.org\/10.1128\/AAC.00437-10. [PubMed]","DOI":"10.1128\/AAC.00437-10"},{"key":"e_1_3_1_143_2","doi-asserted-by":"crossref","unstructured":"Bertsche U Weidenmaier C Kuehner D Yang S-J Baur S Wanner S Francois P Schrenzel J Yeaman MR Bayer AS. 2011. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and d -alanylation. Antimicrob Agents Chemother 55: 3922\u20133928 http:\/\/dx.doi.org\/10.1128\/AAC.01226-10. [PubMed]","DOI":"10.1128\/AAC.01226-10"},{"key":"e_1_3_1_144_2","doi-asserted-by":"crossref","unstructured":"Bertsche U Yang S-J Kuehner D Wanner S Mishra NN Roth T Nega M Schneider A Mayer C Grau T Bayer AS Weidenmaier C. 2013. Increased cell wall teichoic acid production and d -alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS One 8: e67398 http:\/\/dx.doi.org\/10.1371\/journal.pone.0067398. [PubMed]","DOI":"10.1371\/journal.pone.0067398"},{"key":"e_1_3_1_145_2","doi-asserted-by":"crossref","unstructured":"B\u00e6k KT Th\u00f8gersen L Mogenssen RG Mellergaard M Thomsen LE Petersen A Skov S Cameron DR Peleg AY Frees D. 2015. Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene. Antimicrob Agents Chemother 59: 6983\u20136991 http:\/\/dx.doi.org\/10.1128\/AAC.01303-15. [PubMed]","DOI":"10.1128\/AAC.01303-15"},{"key":"e_1_3_1_146_2","doi-asserted-by":"crossref","unstructured":"Cameron DR Mortin LI Rubio A Mylonakis E Moellering RC Jr Eliopoulos GM Peleg AY. 2015. Impact of daptomycin resistance on Staphylococcus aureus virulence. Virulence 6: 127\u2013131 http:\/\/dx.doi.org\/10.1080\/21505594.2015.1011532. [PubMed]","DOI":"10.1080\/21505594.2015.1011532"},{"key":"e_1_3_1_147_2","doi-asserted-by":"crossref","unstructured":"Pader V Hakim S Painter KL Wigneshweraraj S Clarke TB Edwards AM. 2016. Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids. Nat Microbiol 2: 16194 http:\/\/dx.doi.org\/10.1038\/nmicrobiol.2016.194. [PubMed]","DOI":"10.1038\/nmicrobiol.2016.194"},{"key":"e_1_3_1_148_2","doi-asserted-by":"crossref","unstructured":"Mendes RE Deshpande LM Jones RN. 2014. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 17: 1\u201312 http:\/\/dx.doi.org\/10.1016\/j.drup.2014.04.002. [PubMed]","DOI":"10.1016\/j.drup.2014.04.002"},{"key":"e_1_3_1_149_2","doi-asserted-by":"crossref","unstructured":"Cabellos C Garrig\u00f3s C Taberner F Force E Pach\u00f3n-Iba\u00f1ez ME. 2014. Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides. J Infect Chemother 20: 563\u2013568 http:\/\/dx.doi.org\/10.1016\/j.jiac.2014.05.008. [PubMed]","DOI":"10.1016\/j.jiac.2014.05.008"},{"key":"e_1_3_1_150_2","doi-asserted-by":"crossref","unstructured":"Leach KL Swaney SM Colca JR McDonald WG Blinn JR Thomasco LM Gadwood RC Shinabarger D Xiong L Mankin AS. 2007. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 26: 393\u2013402 http:\/\/dx.doi.org\/10.1016\/j.molcel.2007.04.005. [PubMed]","DOI":"10.1016\/j.molcel.2007.04.005"},{"key":"e_1_3_1_151_2","doi-asserted-by":"crossref","unstructured":"Colca JR McDonald WG Waldon DJ Thomasco LM Gadwood RC Lund ET Cavey GS Mathews WR Adams LD Cecil ET Pearson JD Bock JH Mott JE Shinabarger DL Xiong L Mankin AS. 2003. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 278: 21972\u201321979 http:\/\/dx.doi.org\/10.1074\/jbc.M302109200. [PubMed]","DOI":"10.1074\/jbc.M302109200"},{"key":"e_1_3_1_152_2","doi-asserted-by":"crossref","unstructured":"Diep BA Afasizheva A Le HN Kajikawa O Matute-Bello G Tkaczyk C Sellman B Badiou C Lina G Chambers HF. 2013. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 208: 75\u201382 http:\/\/dx.doi.org\/10.1093\/infdis\/jit129. [PubMed]","DOI":"10.1093\/infdis\/jit129"},{"key":"e_1_3_1_153_2","doi-asserted-by":"crossref","unstructured":"Bonn F Pan\u00e9-Farr\u00e9 J Schl\u00fcter R Schaffer M Fuchs S Bernhardt J Riedel K Otto A V\u00f6lker U van Dijl JM Hecker M M\u00e4der U Becher D. 2016. Global analysis of the impact of linezolid onto virulence factor production in S. aureus USA300. Int J Med Microbiol 306: 131\u2013140 http:\/\/dx.doi.org\/10.1016\/j.ijmm.2016.02.004. [PubMed]","DOI":"10.1016\/j.ijmm.2016.02.004"},{"key":"e_1_3_1_154_2","doi-asserted-by":"crossref","unstructured":"Wada A Ohta H Kulthanan K Hiramatsu K. 1993. Molecular cloning and mapping of 16S-23S rRNA gene complexes of Staphylococcus aureus . J Bacteriol 175: 7483\u20137487 http:\/\/dx.doi.org\/10.1128\/jb.175.22.7483-7487.1993. [PubMed]","DOI":"10.1128\/jb.175.22.7483-7487.1993"},{"key":"e_1_3_1_155_2","doi-asserted-by":"crossref","unstructured":"Toh SM Xiong L Arias CA Villegas MV Lolans K Quinn J Mankin AS. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 64: 1506\u20131514 http:\/\/dx.doi.org\/10.1111\/j.1365-2958.2007.05744.x. [PubMed]","DOI":"10.1111\/j.1365-2958.2007.05744.x"},{"key":"e_1_3_1_156_2","doi-asserted-by":"crossref","unstructured":"Tsiodras S Gold HS Sakoulas G Eliopoulos GM Wennersten C Venkataraman L Moellering RC Jr Ferraro MJ. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus . Lancet 358: 207\u2013208 http:\/\/dx.doi.org\/10.1016\/S0140-6736(01)05410-1.","DOI":"10.1016\/S0140-6736(01)05410-1"},{"key":"e_1_3_1_157_2","doi-asserted-by":"crossref","unstructured":"Meka VG Pillai SK Sakoulas G Wennersten C Venkataraman L DeGirolami PC Eliopoulos GM Moellering RC Jr Gold HS. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 190: 311\u2013317 http:\/\/dx.doi.org\/10.1086\/421471. [PubMed]","DOI":"10.1086\/421471"},{"key":"e_1_3_1_158_2","doi-asserted-by":"crossref","unstructured":"Besier S Ludwig A Zander J Brade V Wichelhaus TA. 2008. Linezolid resistance in Staphylococcus aureus : gene dosage effect stability fitness costs and cross-resistances. Antimicrob Agents Chemother 52: 1570\u20131572 http:\/\/dx.doi.org\/10.1128\/AAC.01098-07.","DOI":"10.1128\/AAC.01098-07"},{"key":"e_1_3_1_159_2","doi-asserted-by":"crossref","unstructured":"Locke JB Hilgers M Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 53: 5265\u20135274 http:\/\/dx.doi.org\/10.1128\/AAC.00871-09. [PubMed]","DOI":"10.1128\/AAC.00871-09"},{"key":"e_1_3_1_160_2","doi-asserted-by":"crossref","unstructured":"Tsakris A Pillai SK Gold HS Thauvin-Eliopoulos C Venkataraman L Wennersten C Moellering RC Jr Eliopoulos GM. 2007. Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus . J Antimicrob Chemother 60: 649\u2013651 http:\/\/dx.doi.org\/10.1093\/jac\/dkm246. [PubMed]","DOI":"10.1093\/jac\/dkm246"},{"key":"e_1_3_1_161_2","doi-asserted-by":"crossref","unstructured":"Locke JB Hilgers M Shaw KJ. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother 53: 5275\u20135278 http:\/\/dx.doi.org\/10.1128\/AAC.01032-09. [PubMed]","DOI":"10.1128\/AAC.01032-09"},{"key":"e_1_3_1_162_2","doi-asserted-by":"crossref","unstructured":"Pillai SK Sakoulas G Wennersten C Eliopoulos GM Moellering RC Jr Ferraro MJ Gold HS. 2002. Linezolid resistance in Staphylococcus aureus : characterization and stability of resistant phenotype. J Infect Dis 186: 1603\u20131607 http:\/\/dx.doi.org\/10.1086\/345368. [PubMed]","DOI":"10.1086\/345368"},{"key":"e_1_3_1_163_2","doi-asserted-by":"crossref","unstructured":"Mendes RE Deshpande LM Castanheira M DiPersio J Saubolle MA Jones RN. 2008. First report of cfr -mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 52: 2244\u20132246 http:\/\/dx.doi.org\/10.1128\/AAC.00231-08. [PubMed]","DOI":"10.1128\/AAC.00231-08"},{"key":"e_1_3_1_164_2","doi-asserted-by":"crossref","unstructured":"Morales G Picazo JJ Baos E Candel FJ Arribi A Pel\u00e1ez B Andrade R de la Torre M-\u00c1 Fereres J S\u00e1nchez-Garc\u00eda M. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus . Clin Infect Dis 50: 821\u2013825 http:\/\/dx.doi.org\/10.1086\/650574. [PubMed]","DOI":"10.1086\/650574"},{"key":"e_1_3_1_165_2","doi-asserted-by":"crossref","unstructured":"Kehrenberg C Schwarz S Jacobsen L Hansen LH Vester B. 2005. A new mechanism for chloramphenicol florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol Microbiol 57: 1064\u20131073 http:\/\/dx.doi.org\/10.1111\/j.1365-2958.2005.04754.x. [PubMed]","DOI":"10.1111\/j.1365-2958.2005.04754.x"},{"key":"e_1_3_1_166_2","doi-asserted-by":"crossref","unstructured":"Kehrenberg C Cuny C Strommenger B Schwarz S Witte W. 2009. Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr . Antimicrob Agents Chemother 53: 779\u2013781 http:\/\/dx.doi.org\/10.1128\/AAC.01376-08. [PubMed]","DOI":"10.1128\/AAC.01376-08"},{"key":"e_1_3_1_167_2","doi-asserted-by":"crossref","unstructured":"Shen J Wang Y Schwarz S. 2013. Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 68: 1697\u20131706 http:\/\/dx.doi.org\/10.1093\/jac\/dkt092. [PubMed]","DOI":"10.1093\/jac\/dkt092"},{"key":"e_1_3_1_168_2","doi-asserted-by":"crossref","unstructured":"Cafini F Nguyen TT Higashide M Rom\u00e1n F Prieto J Morikawa K. 2016. Horizontal gene transmission of the cfr gene to MRSA and Enterococcus : role of Staphylococcus epidermidis as a reservoir and alternative pathway for the spread of linezolid resistance. J Antimicrob Chemother 71: 587\u2013592 http:\/\/dx.doi.org\/10.1093\/jac\/dkv391. [PubMed]","DOI":"10.1093\/jac\/dkv391"},{"key":"e_1_3_1_169_2","doi-asserted-by":"crossref","unstructured":"Locke JB Zurenko GE Shaw KJ Bartizal K. 2014. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis 58 (Suppl 1) : S35\u2013S42 http:\/\/dx.doi.org\/10.1093\/cid\/cit616. [PubMed]","DOI":"10.1093\/cid\/cit616"},{"key":"e_1_3_1_170_2","doi-asserted-by":"crossref","unstructured":"Le VT Le HN Pinheiro MG Hahn KJ Dinh ML Larson KB Flanagan SD Badiou C Lina G Tkaczyk C Sellman BR Diep BA. 2017. Effects of tedizolid phosphate on survival outcomes and suppression of production of staphylococcal toxins in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Antimicrob Agents Chemother 61: e02734-16 http:\/\/dx.doi.org\/10.1128\/AAC.02734-16. [PubMed]","DOI":"10.1128\/AAC.02734-16"},{"key":"e_1_3_1_171_2","doi-asserted-by":"crossref","unstructured":"Gu B Kelesidis T Tsiodras S Hindler J Humphries RM. 2013. The emerging problem of linezolid-resistant Staphylococcus . J Antimicrob Chemother 68: 4\u201311 http:\/\/dx.doi.org\/10.1093\/jac\/dks354. [PubMed]","DOI":"10.1093\/jac\/dks354"},{"key":"e_1_3_1_172_2","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Hern\u00e1ndez I Valverde MD D\u00edaz NB Pascual A. 2015. First report of linezolid dependence in methicillin-resistant Staphylococcus aureus . Clin Microbiol Infect 21: 650.e1\u2013650.e4. [PubMed]","DOI":"10.1016\/j.cmi.2015.03.012"},{"key":"e_1_3_1_173_2","doi-asserted-by":"crossref","unstructured":"Liu C Bayer A Cosgrove SE Daum RS Fridkin SK Gorwitz RJ Kaplan SL Karchmer AW Levine DP Murray BE Rybak M Talan DA Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52: 285\u2013292. [PubMed]","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_3_1_174_2","doi-asserted-by":"crossref","unstructured":"Herigon JC Hersh AL Gerber JS Zaoutis TE Newland JG. 2010. Antibiotic management of Staphylococcus aureus infections in US children\u2019s hospitals 1999-2008. Pediatrics 125: e1294\u2013e1300 http:\/\/dx.doi.org\/10.1542\/peds.2009-2867. [PubMed]","DOI":"10.1542\/peds.2009-2867"},{"key":"e_1_3_1_175_2","doi-asserted-by":"crossref","unstructured":"Wilson DN. 2014. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol 12: 35\u201348 http:\/\/dx.doi.org\/10.1038\/nrmicro3155. [PubMed]","DOI":"10.1038\/nrmicro3155"},{"key":"e_1_3_1_176_2","doi-asserted-by":"crossref","unstructured":"Vannuffel P Cocito C. 1996. Mechanism of action of streptogramins and macrolides. Drugs 51 (Suppl 1) : 20\u201330 http:\/\/dx.doi.org\/10.2165\/00003495-199600511-00006. [PubMed]","DOI":"10.2165\/00003495-199600511-00006"},{"key":"e_1_3_1_177_2","doi-asserted-by":"crossref","unstructured":"Hancock RE. 2005. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 5: 209\u2013218 http:\/\/dx.doi.org\/10.1016\/S1473-3099(05)70051-7.","DOI":"10.1016\/S1473-3099(05)70051-7"},{"key":"e_1_3_1_178_2","doi-asserted-by":"crossref","unstructured":"Roberts MC. 2008. Update on macrolide-lincosamide-streptogramin ketolide and oxazolidinone resistance genes. FEMS Microbiol Lett 282: 147\u2013159 http:\/\/dx.doi.org\/10.1111\/j.1574-6968.2008.01145.x. [PubMed]","DOI":"10.1111\/j.1574-6968.2008.01145.x"},{"key":"e_1_3_1_179_2","doi-asserted-by":"crossref","unstructured":"Py\u00f6r\u00e4l\u00e4 S Baptiste KE Catry B van Duijkeren E Greko C Moreno MA Pomba MCMF Rantala M Ru\u017eauskas M Sanders P Threlfall EJ Torren-Edo J T\u00f6rneke K. 2014. Macrolides and lincosamides in cattle and pigs: use and development of antimicrobial resistance. Vet J 200: 230\u2013239 http:\/\/dx.doi.org\/10.1016\/j.tvjl.2014.02.028. [PubMed]","DOI":"10.1016\/j.tvjl.2014.02.028"},{"key":"e_1_3_1_180_2","doi-asserted-by":"crossref","unstructured":"Long KS Poehlsgaard J Kehrenberg C Schwarz S Vester B. 2006. The Cfr rRNA methyltransferase confers resistance to phenicols lincosamides oxazolidinones pleuromutilins and streptogramin A antibiotics. Antimicrob Agents Chemother 50: 2500\u20132505 http:\/\/dx.doi.org\/10.1128\/AAC.00131-06. [PubMed]","DOI":"10.1128\/AAC.00131-06"},{"key":"e_1_3_1_181_2","doi-asserted-by":"crossref","unstructured":"Prunier A-L Malbruny B Tand\u00e9 D Picard B Leclercq R. 2002. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother 46: 3054\u20133056 http:\/\/dx.doi.org\/10.1128\/AAC.46.9.3054-3056.2002. [PubMed]","DOI":"10.1128\/AAC.46.9.3054-3056.2002"},{"key":"e_1_3_1_182_2","doi-asserted-by":"crossref","unstructured":"Prunier A-L Malbruny B Laurans M Brouard J Duhamel J-F Leclercq R. 2003. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187: 1709\u20131716 http:\/\/dx.doi.org\/10.1086\/374937. [PubMed]","DOI":"10.1086\/374937"},{"key":"e_1_3_1_183_2","doi-asserted-by":"crossref","unstructured":"Wright GD. 2005. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev 57: 1451\u20131470 http:\/\/dx.doi.org\/10.1016\/j.addr.2005.04.002. [PubMed]","DOI":"10.1016\/j.addr.2005.04.002"},{"key":"e_1_3_1_184_2","doi-asserted-by":"crossref","unstructured":"Poole K. 2005. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20\u201351 http:\/\/dx.doi.org\/10.1093\/jac\/dki171. [PubMed]","DOI":"10.1093\/jac\/dki171"},{"key":"e_1_3_1_185_2","doi-asserted-by":"crossref","unstructured":"Reynolds E Ross JI Cove JH. 2003. msr (A) and related macrolide\/streptogramin resistance determinants: incomplete transporters? Int J Antimicrob Agents 22: 228\u2013236 http:\/\/dx.doi.org\/10.1016\/S0924-8579(03)00218-8.","DOI":"10.1016\/S0924-8579(03)00218-8"},{"key":"e_1_3_1_186_2","doi-asserted-by":"crossref","unstructured":"Gentry DR McCloskey L Gwynn MN Rittenhouse SF Scangarella N Shawar R Holmes DJ. 2008. Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus . Antimicrob Agents Chemother 52: 4507\u20134509 http:\/\/dx.doi.org\/10.1128\/AAC.00915-08. [PubMed]","DOI":"10.1128\/AAC.00915-08"},{"key":"e_1_3_1_187_2","doi-asserted-by":"crossref","unstructured":"Floyd JL Smith KP Kumar SH Floyd JT Varela MF. 2010. LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus . Antimicrob Agents Chemother 54: 5406\u20135412 http:\/\/dx.doi.org\/10.1128\/AAC.00580-10. [PubMed]","DOI":"10.1128\/AAC.00580-10"},{"key":"e_1_3_1_188_2","doi-asserted-by":"crossref","unstructured":"Huang J O\u2019Toole PW Shen W Amrine-Madsen H Jiang X Lobo N Palmer LM Voelker L Fan F Gwynn MN McDevitt D. 2004. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus . Antimicrob Agents Chemother 48: 909\u2013917 http:\/\/dx.doi.org\/10.1128\/AAC.48.3.909-917.2004. [PubMed]","DOI":"10.1128\/AAC.48.3.909-917.2004"},{"key":"e_1_3_1_189_2","doi-asserted-by":"crossref","unstructured":"Cunha BA. 2001. Antibiotic side effects. Med Clin North Am 85: 149\u2013185.","DOI":"10.1016\/S0025-7125(05)70309-6"},{"key":"e_1_3_1_190_2","doi-asserted-by":"crossref","unstructured":"Fraunfelder FW Fraunfelder FT. 2013. Restricting topical ocular chloramphenicol eye drop use in the United States. Did we overreact? Am J Ophthalmol 156: 420\u2013422 http:\/\/dx.doi.org\/10.1016\/j.ajo.2013.05.004. [PubMed]","DOI":"10.1016\/j.ajo.2013.05.004"},{"key":"e_1_3_1_191_2","doi-asserted-by":"crossref","unstructured":"Schwarz S Kehrenberg C Doublet B Cloeckaert A. 2004. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 28: 519\u2013542 http:\/\/dx.doi.org\/10.1016\/j.femsre.2004.04.001. [PubMed]","DOI":"10.1016\/j.femsre.2004.04.001"},{"key":"e_1_3_1_192_2","doi-asserted-by":"crossref","unstructured":"Lyon BR Skurray R. 1987. Antimicrobial resistance of Staphylococcus aureus : genetic basis. Microbiol Rev 51: 88\u2013134. [PubMed]","DOI":"10.1128\/mr.51.1.88-134.1987"},{"key":"e_1_3_1_193_2","doi-asserted-by":"crossref","unstructured":"Kehrenberg C Schwarz S. 2006. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates . Antimicrob Agents Chemother 50: 1156\u20131163 http:\/\/dx.doi.org\/10.1128\/AAC.50.4.1156-1163.2006. [PubMed]","DOI":"10.1128\/AAC.50.4.1156-1163.2006"},{"key":"e_1_3_1_194_2","doi-asserted-by":"crossref","unstructured":"Novak R. 2011. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci 1241: 71\u201381 http:\/\/dx.doi.org\/10.1111\/j.1749-6632.2011.06219.x. [PubMed]","DOI":"10.1111\/j.1749-6632.2011.06219.x"},{"key":"e_1_3_1_195_2","doi-asserted-by":"crossref","unstructured":"Yang LP Keam SJ. 2008. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 68: 855\u2013873 http:\/\/dx.doi.org\/10.2165\/00003495-200868060-00008. [PubMed]","DOI":"10.2165\/00003495-200868060-00008"},{"key":"e_1_3_1_196_2","doi-asserted-by":"crossref","unstructured":"Kosowska-Shick K Clark C Credito K McGhee P Dewasse B Bogdanovich T Appelbaum PC. 2006. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes . Antimicrob Agents Chemother 50: 765\u2013769 http:\/\/dx.doi.org\/10.1128\/AAC.50.2.765-769.2006. [PubMed]","DOI":"10.1128\/AAC.50.2.765-769.2006"},{"key":"e_1_3_1_197_2","doi-asserted-by":"crossref","unstructured":"Gentry DR Rittenhouse SF McCloskey L Holmes DJ. 2007. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother 51: 2048\u20132052 http:\/\/dx.doi.org\/10.1128\/AAC.01066-06. [PubMed]","DOI":"10.1128\/AAC.01066-06"},{"key":"e_1_3_1_198_2","doi-asserted-by":"crossref","unstructured":"Kadlec K Fessler AT Hauschild T Schwarz S. 2012. Novel and uncommon antimicrobial resistance genes in livestock-associated methicillin-resistant Staphylococcus aureus . Clin Microbiol Infect 18: 745\u2013755 http:\/\/dx.doi.org\/10.1111\/j.1469-0691.2012.03842.x. [PubMed]","DOI":"10.1111\/j.1469-0691.2012.03842.x"},{"key":"e_1_3_1_199_2","doi-asserted-by":"crossref","unstructured":"Magnet S Blanchard JS. 2005. Molecular insights into aminoglycoside action and resistance. Chem Rev 105: 477\u2013498 http:\/\/dx.doi.org\/10.1021\/cr0301088. [PubMed]","DOI":"10.1021\/cr0301088"},{"key":"e_1_3_1_200_2","doi-asserted-by":"crossref","unstructured":"Kotra LP Haddad J Mobashery S. 2000. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44: 3249\u20133256 http:\/\/dx.doi.org\/10.1128\/AAC.44.12.3249-3256.2000. [PubMed]","DOI":"10.1128\/AAC.44.12.3249-3256.2000"},{"key":"e_1_3_1_201_2","doi-asserted-by":"crossref","unstructured":"Garneau-Tsodikova S Labby KJ. 2016. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. Medchemcomm 7: 11\u201327 http:\/\/dx.doi.org\/10.1039\/C5MD00344J. [PubMed]","DOI":"10.1039\/C5MD00344J"},{"key":"e_1_3_1_202_2","doi-asserted-by":"crossref","unstructured":"Ramirez MS Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat 13: 151\u2013171 http:\/\/dx.doi.org\/10.1016\/j.drup.2010.08.003.","DOI":"10.1016\/j.drup.2010.08.003"},{"key":"e_1_3_1_203_2","doi-asserted-by":"crossref","unstructured":"Daigle DM Hughes DW Wright GD. 1999. Prodigious substrate specificity of AAC(6\u2032)-APH(2\u2033) an aminoglycoside antibiotic resistance determinant in enterococci and staphylococci. Chem Biol 6: 99\u2013110 http:\/\/dx.doi.org\/10.1016\/S1074-5521(99)80006-4.","DOI":"10.1016\/S1074-5521(99)80006-4"},{"key":"e_1_3_1_204_2","doi-asserted-by":"crossref","unstructured":"Proctor RA von Eiff C Kahl BC Becker K McNamara P Herrmann M Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4: 295\u2013305 http:\/\/dx.doi.org\/10.1038\/nrmicro1384.","DOI":"10.1038\/nrmicro1384"},{"key":"e_1_3_1_205_2","doi-asserted-by":"crossref","unstructured":"Kahl BC Becker K L\u00f6ffler B. 2016. Clinical significance and pathogenesis of staphylococcal small colony variants in persistent infections. Clin Microbiol Rev 29: 401\u2013427 http:\/\/dx.doi.org\/10.1128\/CMR.00069-15.","DOI":"10.1128\/CMR.00069-15"},{"key":"e_1_3_1_206_2","doi-asserted-by":"crossref","unstructured":"Takahashi Y Igarashi M. 2017. Destination of aminoglycoside antibiotics in the \u2018post-antibiotic era\u2019. J Antibiot (Tokyo) . doi:10.1038\/ja.2017.117.","DOI":"10.1038\/ja.2017.117"},{"key":"e_1_3_1_207_2","doi-asserted-by":"crossref","unstructured":"Wachino J Shibayama K Kimura K Yamane K Suzuki S Arakawa Y. 2010. RmtC introduces G1405 methylation in 16S rRNA and confers high-level aminoglycoside resistance on Gram-positive microorganisms. FEMS Microbiol Lett 311: 56\u201360 http:\/\/dx.doi.org\/10.1111\/j.1574-6968.2010.02068.x.","DOI":"10.1111\/j.1574-6968.2010.02068.x"},{"key":"e_1_3_1_208_2","doi-asserted-by":"crossref","unstructured":"Zhanel GG Karlowsky JA Rubinstein E Hoban DJ. 2006. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 4: 9\u201325 http:\/\/dx.doi.org\/10.1586\/14787210.4.1.9.","DOI":"10.1586\/14787210.4.1.9"},{"key":"e_1_3_1_209_2","doi-asserted-by":"crossref","unstructured":"Chopra I Roberts M. 2001. Tetracycline antibiotics: mode of action applications molecular biology and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65: 232\u2013260 http:\/\/dx.doi.org\/10.1128\/MMBR.65.2.232-260.2001.","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_1_210_2","doi-asserted-by":"crossref","unstructured":"Nelson ML Levy SB. 2011. The history of the tetracyclines. Ann N Y Acad Sci 1241: 17\u201332 http:\/\/dx.doi.org\/10.1111\/j.1749-6632.2011.06354.x.","DOI":"10.1111\/j.1749-6632.2011.06354.x"},{"key":"e_1_3_1_211_2","doi-asserted-by":"crossref","unstructured":"Kasbekar N. 2006. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm 63: 1235\u20131243 http:\/\/dx.doi.org\/10.2146\/ajhp050487.","DOI":"10.2146\/ajhp050487"},{"key":"e_1_3_1_212_2","doi-asserted-by":"crossref","unstructured":"Jensen SO Lyon BR. 2009. Genetics of antimicrobial resistance in Staphylococcus aureus . Future Microbiol 4: 565\u2013582 http:\/\/dx.doi.org\/10.2217\/fmb.09.30.","DOI":"10.2217\/fmb.09.30"},{"key":"e_1_3_1_213_2","doi-asserted-by":"crossref","unstructured":"Li S Skov RL Han X Larsen AR Larsen J S\u00f8rum M Wulf M Voss A Hiramatsu K Ito T. 2011. Novel types of staphylococcal cassette chromosome mec elements identified in clonal complex 398 methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 55: 3046\u20133050 http:\/\/dx.doi.org\/10.1128\/AAC.01475-10.","DOI":"10.1128\/AAC.01475-10"},{"key":"e_1_3_1_214_2","doi-asserted-by":"crossref","unstructured":"Truong-Bolduc QC Dunman PM Strahilevitz J Projan SJ Hooper DC. 2005. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus . J Bacteriol 187: 2395\u20132405 http:\/\/dx.doi.org\/10.1128\/JB.187.7.2395-2405.2005.","DOI":"10.1128\/JB.187.7.2395-2405.2005"},{"key":"e_1_3_1_215_2","doi-asserted-by":"crossref","unstructured":"Connell SR Tracz DM Nierhaus KH Taylor DE. 2003. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 47: 3675\u20133681 http:\/\/dx.doi.org\/10.1128\/AAC.47.12.3675-3681.2003.","DOI":"10.1128\/AAC.47.12.3675-3681.2003"},{"key":"e_1_3_1_216_2","doi-asserted-by":"crossref","unstructured":"Schmitz F-J Krey A Sadurski R Verhoef J Milatovic D Fluit AC European SENTRY Participants. 2001. Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. J Antimicrob Chemother 47: 239\u2013240 http:\/\/dx.doi.org\/10.1093\/jac\/47.2.239.","DOI":"10.1093\/jac\/47.2.239"},{"key":"e_1_3_1_217_2","doi-asserted-by":"crossref","unstructured":"Larsen J Clasen J Hansen JE Paulander W Petersen A Larsen AR Frees D. 2016. Copresence of tet (K) and tet (M) in livestock-associated methicillin-resistant Staphylococcus aureus clonal complex 398 is associated with increased fitness during exposure to sublethal concentrations of tetracycline. Antimicrob Agents Chemother 60: 4401\u20134403 http:\/\/dx.doi.org\/10.1128\/AAC.00426-16.","DOI":"10.1128\/AAC.00426-16"},{"key":"e_1_3_1_218_2","doi-asserted-by":"crossref","unstructured":"Fluit AC Florijn A Verhoef J Milatovic D. 2005. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 49: 1636\u20131638 http:\/\/dx.doi.org\/10.1128\/AAC.49.4.1636-1638.2005.","DOI":"10.1128\/AAC.49.4.1636-1638.2005"},{"key":"e_1_3_1_219_2","doi-asserted-by":"crossref","unstructured":"Sun Y Cai Y Liu X Bai N Liang B Wang R. 2013. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 41: 110\u2013116 http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2012.09.005.","DOI":"10.1016\/j.ijantimicag.2012.09.005"},{"key":"e_1_3_1_220_2","doi-asserted-by":"crossref","unstructured":"Sader HS Farrell DJ Flamm RK Jones RN. 2014. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother 58: 2274\u20132280 http:\/\/dx.doi.org\/10.1128\/AAC.02684-13.","DOI":"10.1128\/AAC.02684-13"},{"key":"e_1_3_1_221_2","doi-asserted-by":"crossref","unstructured":"Garza-Gonz\u00e1lez E Llaca-D\u00edaz JM Bosques-Padilla FJ Gonz\u00e1lez GM. 2010. Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii . Chemotherapy 56: 275\u2013279 http:\/\/dx.doi.org\/10.1159\/000319903.","DOI":"10.1159\/000319903"},{"key":"e_1_3_1_222_2","doi-asserted-by":"crossref","unstructured":"McAleese F Petersen P Ruzin A Dunman PM Murphy E Projan SJ Bradford PA. 2005. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49: 1865\u20131871 http:\/\/dx.doi.org\/10.1128\/AAC.49.5.1865-1871.2005.","DOI":"10.1128\/AAC.49.5.1865-1871.2005"},{"key":"e_1_3_1_223_2","doi-asserted-by":"crossref","unstructured":"Dabul ANG Avaca-Crusca JS Van Tyne D Gilmore MS Camargo ILBC. 2017. Resistance in in vitro selected tigecycline-resistant methicillin-resistant Staphylococcus aureus sequence type 5 is driven by mutations in mepR and mepA genes. Microbial Drug Resist 24: 519\u2013526.","DOI":"10.1089\/mdr.2017.0279"},{"key":"e_1_3_1_224_2","doi-asserted-by":"crossref","unstructured":"Beabout K Hammerstrom TG Perez AM Magalh\u00e3es BF Prater AG Clements TP Arias CA Saxer G Shamoo Y. 2015. The ribosomal S10 protein is a general target for decreased tigecycline susceptibility. Antimicrob Agents Chemother 59: 5561\u20135566 http:\/\/dx.doi.org\/10.1128\/AAC.00547-15.","DOI":"10.1128\/AAC.00547-15"},{"key":"e_1_3_1_225_2","doi-asserted-by":"crossref","unstructured":"Thomas CM Hothersall J Willis CL Simpson TJ. 2010. Resistance to and synthesis of the antibiotic mupirocin. Nat Rev Microbiol 8: 281\u2013289 http:\/\/dx.doi.org\/10.1038\/nrmicro2278.","DOI":"10.1038\/nrmicro2278"},{"key":"e_1_3_1_226_2","doi-asserted-by":"crossref","unstructured":"Diep BA Gill SR Chang RF Phan TH Chen JH Davidson MG Lin F Lin J Carleton HA Mongodin EF Sensabaugh GF Perdreau-Remington F. 2006. Complete genome sequence of USA300 an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus . Lancet 367: 731\u2013739 http:\/\/dx.doi.org\/10.1016\/S0140-6736(06)68231-7.","DOI":"10.1016\/S0140-6736(06)68231-7"},{"key":"e_1_3_1_227_2","doi-asserted-by":"crossref","unstructured":"Seah C Alexander DC Louie L Simor A Low DE Longtin J Melano RG. 2012. MupB a new high-level mupirocin resistance mechanism in Staphylococcus aureus . Antimicrob Agents Chemother 56: 1916\u20131920 http:\/\/dx.doi.org\/10.1128\/AAC.05325-11.","DOI":"10.1128\/AAC.05325-11"},{"key":"e_1_3_1_228_2","doi-asserted-by":"crossref","unstructured":"Howden BP Grayson ML. 2006. Dumb and dumber: the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus . Clin Infect Dis 42: 394\u2013400 http:\/\/dx.doi.org\/10.1086\/499365.","DOI":"10.1086\/499365"},{"key":"e_1_3_1_229_2","doi-asserted-by":"crossref","unstructured":"O\u2019Neill AJ Cove JH Chopra I. 2001. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus . J Antimicrob Chemother 47: 647\u2013650 http:\/\/dx.doi.org\/10.1093\/jac\/47.5.647.","DOI":"10.1093\/jac\/47.5.647"},{"key":"e_1_3_1_230_2","doi-asserted-by":"crossref","unstructured":"Farrell DJ Castanheira M Chopra I. 2011. Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 52 (Suppl 7) : S487\u2013S492 http:\/\/dx.doi.org\/10.1093\/cid\/cir164.","DOI":"10.1093\/cid\/cir164"},{"key":"e_1_3_1_231_2","doi-asserted-by":"crossref","unstructured":"Norstr\u00f6m T Lannerg\u00e5rd J Hughes D. 2007. Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus . Antimicrob Agents Chemother 51: 4438\u20134446 http:\/\/dx.doi.org\/10.1128\/AAC.00328-07. [PubMed]","DOI":"10.1128\/AAC.00328-07"},{"key":"e_1_3_1_232_2","doi-asserted-by":"crossref","unstructured":"Lannerg\u00e5rd J Cao S Norstr\u00f6m T Delgado A Gustafson JE Hughes D. 2011. Genetic complexity of fusidic acid-resistant small colony variants (SCV) in Staphylococcus aureus . PLoS One 6: e28366. [PubMed]","DOI":"10.1371\/journal.pone.0028366"},{"key":"e_1_3_1_233_2","doi-asserted-by":"crossref","unstructured":"O\u2019Neill AJ McLaws F Kahlmeter G Henriksen AS Chopra I. 2007. Genetic basis of resistance to fusidic acid in staphylococci. Antimicrob Agents Chemother 51: 1737\u20131740 http:\/\/dx.doi.org\/10.1128\/AAC.01542-06. [PubMed]","DOI":"10.1128\/AAC.01542-06"},{"key":"e_1_3_1_234_2","doi-asserted-by":"crossref","unstructured":"Cox G Thompson GS Jenkins HT Peske F Savelsbergh A Rodnina MV Wintermeyer W Homans SW Edwards TA O\u2019Neill AJ. 2012. Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid. Proc Natl Acad Sci U S A 109: 2102\u20132107 http:\/\/dx.doi.org\/10.1073\/pnas.1117275109. [PubMed]","DOI":"10.1073\/pnas.1117275109"},{"key":"e_1_3_1_235_2","doi-asserted-by":"crossref","unstructured":"Holden MT Feil EJ Lindsay JA Peacock SJ Day NP Enright MC Foster TJ Moore CE Hurst L Atkin R Barron A Bason N Bentley SD Chillingworth C Chillingworth T Churcher C Clark L Corton C Cronin A Doggett J Dowd L Feltwell T Hance Z Harris B Hauser H Holroyd S Jagels K James KD Lennard N Line A Mayes R Moule S Mungall K Ormond D Quail MA Rabbinowitsch E Rutherford K Sanders M Sharp S Simmonds M Stevens K Whitehead S Barrell BG Spratt BG Parkhill J. 2004. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci U S A 101: 9786\u20139791 http:\/\/dx.doi.org\/10.1073\/pnas.0402521101. [PubMed]","DOI":"10.1073\/pnas.0402521101"},{"key":"e_1_3_1_236_2","doi-asserted-by":"crossref","unstructured":"O\u2019Neill AJ Larsen AR Skov R Henriksen AS Chopra I. 2007. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus . J Clin Microbiol 45: 1505\u20131510 http:\/\/dx.doi.org\/10.1128\/JCM.01984-06. [PubMed]","DOI":"10.1128\/JCM.01984-06"},{"key":"e_1_3_1_237_2","doi-asserted-by":"crossref","unstructured":"Chen H-J Chang Y-C Tsai J-C Hung W-C Lin Y-T You S-J Tseng S-P Teng L-J. 2013. New structure of phage-related islands carrying fusB and a virulence gene in fusidic acid-resistant Staphylococcus epidermidis . Antimicrob Agents Chemother 57: 5737\u20135739 http:\/\/dx.doi.org\/10.1128\/AAC.01433-13. [PubMed]","DOI":"10.1128\/AAC.01433-13"},{"key":"e_1_3_1_238_2","doi-asserted-by":"crossref","unstructured":"Blondeau JM. 2004. Fluoroquinolones: mechanism of action classification and development of resistance. Surv Ophthalmol 49 (Suppl 2) : S73\u2013S78 http:\/\/dx.doi.org\/10.1016\/j.survophthal.2004.01.005. [PubMed]","DOI":"10.1016\/j.survophthal.2004.01.005"},{"key":"e_1_3_1_239_2","doi-asserted-by":"crossref","unstructured":"Gade ND Qazi MS. 2013. Fluoroquinolone therapy in Staphylococcus aureus infections: where do we stand? J Lab Physicians 5: 109\u2013112 http:\/\/dx.doi.org\/10.4103\/0974-2727.119862. [PubMed]","DOI":"10.4103\/0974-2727.119862"},{"key":"e_1_3_1_240_2","doi-asserted-by":"crossref","unstructured":"MacDougall C Powell JP Johnson CK Edmond MB Polk RE. 2005. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 41: 435\u2013440 http:\/\/dx.doi.org\/10.1086\/432056. [PubMed]","DOI":"10.1086\/432056"},{"key":"e_1_3_1_241_2","doi-asserted-by":"crossref","unstructured":"Foster TJ. 2017. Antibiotic resistance in Staphylococcus aureus . Current status and future prospects. FEMS Microbiol Rev 41: 430\u2013449 http:\/\/dx.doi.org\/10.1093\/femsre\/fux007. [PubMed]","DOI":"10.1093\/femsre\/fux007"},{"key":"e_1_3_1_242_2","doi-asserted-by":"crossref","unstructured":"Tanaka M Wang T Onodera Y Uchida Y Sato K. 2000. Mechanism of quinolone resistance in Staphylococcus aureus . J Infect Chemother 6: 131\u2013139 http:\/\/dx.doi.org\/10.1007\/s101560070010. [PubMed]","DOI":"10.1007\/s101560070010"},{"key":"e_1_3_1_243_2","doi-asserted-by":"crossref","unstructured":"Ince D Hooper DC. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus . Antimicrob Agents Chemother 45: 2755\u20132764 http:\/\/dx.doi.org\/10.1128\/AAC.45.10.2755-2764.2001. [PubMed]","DOI":"10.1128\/AAC.45.10.2755-2764.2001"},{"key":"e_1_3_1_244_2","doi-asserted-by":"crossref","unstructured":"Hooper DC. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 31 (Suppl 2) : S24\u2013S28 http:\/\/dx.doi.org\/10.1086\/314056. [PubMed]","DOI":"10.1086\/314056"},{"key":"e_1_3_1_245_2","doi-asserted-by":"crossref","unstructured":"Floss HG Yu T-W. 2005. Rifamycin-mode of action resistance and biosynthesis. Chem Rev 105: 621\u2013632 http:\/\/dx.doi.org\/10.1021\/cr030112j. [PubMed]","DOI":"10.1021\/cr030112j"},{"key":"e_1_3_1_246_2","doi-asserted-by":"crossref","unstructured":"Wichelhaus TA B\u00f6ddinghaus B Besier S Sch\u00e4fer V Brade V Ludwig A. 2002. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus . Antimicrob Agents Chemother 46: 3381\u20133385 http:\/\/dx.doi.org\/10.1128\/AAC.46.11.3381-3385.2002. [PubMed]","DOI":"10.1128\/AAC.46.11.3381-3385.2002"},{"key":"e_1_3_1_247_2","doi-asserted-by":"crossref","unstructured":"Bradley P Gordon NC Walker TM Dunn L Heys S Huang B Earle S Pankhurst LJ Anson L de Cesare M Piazza P Votintseva AA Golubchik T Wilson DJ Wyllie DH Diel R Niemann S Feuerriegel S Kohl TA Ismail N Omar SV Smith EG Buck D McVean G Walker AS Peto TE Crook DW Iqbal Z. 2015. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis . Nat Commun 6: 10063 http:\/\/dx.doi.org\/10.1038\/ncomms10063. [PubMed]","DOI":"10.1038\/ncomms10063"},{"key":"e_1_3_1_248_2","doi-asserted-by":"crossref","unstructured":"Huovinen P Huovinen P. 2001. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 32: 1608\u20131614 http:\/\/dx.doi.org\/10.1086\/320532. [PubMed]","DOI":"10.1086\/320532"},{"key":"e_1_3_1_249_2","doi-asserted-by":"crossref","unstructured":"Hampele IC D\u2019Arcy A Dale GE Kostrewa D Nielsen J Oefner C Page MG Sch\u00f6nfeld H-J St\u00fcber D Then RL. 1997. Structure and function of the dihydropteroate synthase from Staphylococcus aureus . J Mol Biol 268: 21\u201330. http:\/\/dx.doi.org\/10.1006\/jmbi.1997.0944. [PubMed]","DOI":"10.1006\/jmbi.1997.0944"},{"key":"e_1_3_1_250_2","doi-asserted-by":"crossref","unstructured":"Vickers AA Potter NJ Fishwick CW Chopra I O\u2019Neill AJ. 2009. Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J Antimicrob Chemother 63: 1112\u20131117 http:\/\/dx.doi.org\/10.1093\/jac\/dkp090. [PubMed]","DOI":"10.1093\/jac\/dkp090"},{"key":"e_1_3_1_251_2","doi-asserted-by":"crossref","unstructured":"Nurjadi D Sch\u00e4fer J Friedrich-J\u00e4nicke B Mueller A Neumayr A Calvo-Cano A Goorhuis A Molhoek N Lagler H Kantele A. 2015. Predominance of dfrG as determinant of trimethoprim resistance in imported Staphylococcus aureus . Clin Microbiol Infect 21: 1095.e5\u20131095.e9. [PubMed]","DOI":"10.1016\/j.cmi.2015.08.021"},{"key":"e_1_3_1_252_2","doi-asserted-by":"crossref","unstructured":"Kriegeskorte A Lor\u00e8 NI Bragonzi A Riva C Kelkenberg M Becker K Proctor RA Peters G Kahl BC. 2015. Thymidine-dependent Staphylococcus aureus small-colony variants are induced by trimethoprim-sulfamethoxazole (SXT) and have increased fitness during SXT challenge. Antimicrob Agents Chemother 59: 7265\u20137272 http:\/\/dx.doi.org\/10.1128\/AAC.00742-15.","DOI":"10.1128\/AAC.00742-15"},{"key":"e_1_3_1_253_2","doi-asserted-by":"crossref","unstructured":"Chatterjee I Kriegeskorte A Fischer A Deiwick S Theimann N Proctor RA Peters G Herrmann M Kahl BC. 2008. In vivo mutations of thymidylate synthase (encoded by thyA ) are responsible for thymidine dependency in clinical small-colony variants of Staphylococcus aureus . J Bacteriol 190: 834\u2013842 http:\/\/dx.doi.org\/10.1128\/JB.00912-07.","DOI":"10.1128\/JB.00912-07"},{"key":"e_1_3_1_254_2","doi-asserted-by":"crossref","unstructured":"Besier S Zander J Siegel E Saum SH Hunfeld K-P Ehrhart A Brade V Wichelhaus TA. 2008. Thymidine-dependent Staphylococcus aureus small-colony variants: human pathogens that are relevant not only in cases of cystic fibrosis lung disease. J Clin Microbiol 46: 3829\u20133832 http:\/\/dx.doi.org\/10.1128\/JCM.01440-08.","DOI":"10.1128\/JCM.01440-08"},{"key":"e_1_3_1_255_2","unstructured":"WHO. 2017. Antibacterial Agents in Clinical Development: an Analysis of the Antibacterial Clinical Development Pipeline Including Tuberculosis . World Health Organization Geneva Switzerland."},{"key":"e_1_3_1_256_2","doi-asserted-by":"crossref","unstructured":"Remy JM Tow-Keogh CA McConnell TS Dalton JM Devito JA. 2012. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus : resistance selection and characterization. J Antimicrob Chemother 67: 2814\u20132820 http:\/\/dx.doi.org\/10.1093\/jac\/dks307.","DOI":"10.1093\/jac\/dks307"},{"key":"e_1_3_1_257_2","doi-asserted-by":"crossref","unstructured":"Butler MS Blaskovich MA Cooper MA. 2016. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot (Tokyo) 70: 3\u201324.","DOI":"10.1038\/ja.2016.72"},{"key":"e_1_3_1_258_2","doi-asserted-by":"crossref","unstructured":"Mensa B Howell GL Scott R DeGrado WF. 2014. Comparative mechanistic studies of brilacidin daptomycin and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58: 5136\u20135145 http:\/\/dx.doi.org\/10.1128\/AAC.02955-14.","DOI":"10.1128\/AAC.02955-14"},{"key":"e_1_3_1_259_2","doi-asserted-by":"crossref","unstructured":"Vermote A Van Calenbergh S. 2017. Small-molecule potentiators for conventional antibiotics against Staphylococcus aureus . ACS Infect Dis 3: 780\u2013796 http:\/\/dx.doi.org\/10.1021\/acsinfecdis.7b00084.","DOI":"10.1021\/acsinfecdis.7b00084"},{"key":"e_1_3_1_260_2","doi-asserted-by":"crossref","unstructured":"Vestergaard M N\u00f8hr-Meldgaard K Bojer MS Krogsg\u00e5rd Nielsen C Meyer RL Slavetinsky C Peschel A Ingmer H. 2017. Inhibition of the ATP synthase eliminates the intrinsic resistance of Staphylococcus aureus towards polymyxins. MBio 8: e01114-17 http:\/\/dx.doi.org\/10.1128\/mBio.01114-17.","DOI":"10.1128\/mBio.01114-17"},{"key":"e_1_3_1_261_2","doi-asserted-by":"crossref","unstructured":"Klitgaard JK Skov MN Kallipolitis BH Kolmos HJ. 2008. Reversal of methicillin resistance in Staphylococcus aureus by thioridazine. J Antimicrob Chemother 62: 1215\u20131221 http:\/\/dx.doi.org\/10.1093\/jac\/dkn417.","DOI":"10.1093\/jac\/dkn417"},{"key":"e_1_3_1_262_2","unstructured":"Rasmussen KS Poulsen M\u00d8 Jacobsen K Skov MN Kolmos HJ Kallipolitis BH Klitgaard JK. 2017. Combination of thioridazine and dicloxacillin as a possible treatment strategy of staphylococci. New Microbiol 40: 146\u2013147."},{"key":"e_1_3_1_263_2","doi-asserted-by":"crossref","unstructured":"Czaplewski L Bax R Clokie M Dawson M Fairhead H Fischetti VA Foster S Gilmore BF Hancock RE Harper D Henderson IR Hilpert K Jones BV Kadioglu A Knowles D \u00d3lafsd\u00f3ttir S Payne D Projan S Shaunak S Silverman J Thomas CM Trust TJ Warn P Rex JH. 2016. Alternatives to antibiotics: a pipeline portfolio review. Lancet Infect Dis 16: 239\u2013251 http:\/\/dx.doi.org\/10.1016\/S1473-3099(15)00466-1.","DOI":"10.1016\/S1473-3099(15)00466-1"},{"key":"e_1_3_1_264_2","doi-asserted-by":"crossref","unstructured":"Bebbington C Yarranton G. 2008. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 19: 613\u2013619 http:\/\/dx.doi.org\/10.1016\/j.copbio.2008.10.002.","DOI":"10.1016\/j.copbio.2008.10.002"},{"key":"e_1_3_1_265_2","doi-asserted-by":"crossref","unstructured":"Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339: 520\u2013532 http:\/\/dx.doi.org\/10.1056\/NEJM199808203390806.","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_1_266_2","doi-asserted-by":"crossref","unstructured":"Lehar SM Pillow T Xu M Staben L Kajihara KK Vandlen R DePalatis L Raab H Hazenbos WL Morisaki JH Kim J Park S Darwish M Lee BC Hernandez H Loyet KM Lupardus P Fong R Yan D Chalouni C Luis E Khalfin Y Plise E Cheong J Lyssikatos JP Strandh M Koefoed K Andersen PS Flygare JA Wah Tan M Brown EJ Mariathasan S. 2015. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus . Nature 527: 323\u2013328 http:\/\/dx.doi.org\/10.1038\/nature16057.","DOI":"10.1038\/nature16057"},{"key":"e_1_3_1_267_2","doi-asserted-by":"crossref","unstructured":"Rasko DA Sperandio V. 2010. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9: 117\u2013128 http:\/\/dx.doi.org\/10.1038\/nrd3013.","DOI":"10.1038\/nrd3013"},{"key":"e_1_3_1_268_2","doi-asserted-by":"crossref","unstructured":"Nielsen A M\u00e5nsson M Bojer MS Gram L Larsen TO Novick RP Frees D Fr\u00f8ki\u00e6r H Ingmer H. 2014. Solonamide B inhibits quorum sensing and reduces Staphylococcus aureus mediated killing of human neutrophils. PLoS One 9: e84992 http:\/\/dx.doi.org\/10.1371\/journal.pone.0084992.","DOI":"10.1371\/journal.pone.0084992"},{"key":"e_1_3_1_269_2","doi-asserted-by":"crossref","unstructured":"Dickey SW Cheung GYC Otto M. 2017. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov 16: 457\u2013471 http:\/\/dx.doi.org\/10.1038\/nrd.2017.23.","DOI":"10.1038\/nrd.2017.23"},{"key":"e_1_3_1_270_2","doi-asserted-by":"crossref","unstructured":"Baldry M Nielsen A Bojer MS Zhao Y Friberg C Ifrah D Glasser Heede N Larsen TO Fr\u00f8ki\u00e6r H Frees D Zhang L Dai H Ingmer H. 2016. Norlichexanthone reduces virulence gene expression and biofilm formation in Staphylococcus aureus . PLoS One 11: e0168305 http:\/\/dx.doi.org\/10.1371\/journal.pone.0168305.","DOI":"10.1371\/journal.pone.0168305"},{"key":"e_1_3_1_271_2","doi-asserted-by":"crossref","unstructured":"Mayville P Ji G Beavis R Yang H Goger M Novick RP Muir TW. 1999. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc Natl Acad Sci U S A 96: 1218\u20131223 http:\/\/dx.doi.org\/10.1073\/pnas.96.4.1218.","DOI":"10.1073\/pnas.96.4.1218"},{"key":"e_1_3_1_272_2","doi-asserted-by":"crossref","unstructured":"Paharik AE Parlet CP Chung N Todd DA Rodriguez EI Van Dyke MJ Cech NB Horswill AR. 2017. Coagulase-negative staphylococcal strain prevents Staphylococcus aureus colonization and skin infection by blocking quorum sensing. Cell Host Microbe 22: 746\u2013756.e5 http:\/\/dx.doi.org\/10.1016\/j.chom.2017.11.001.","DOI":"10.1016\/j.chom.2017.11.001"},{"key":"e_1_3_1_273_2","doi-asserted-by":"crossref","unstructured":"Sulakvelidze A Alavidze Z Morris JG Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45: 649\u2013659 http:\/\/dx.doi.org\/10.1128\/AAC.45.3.649-659.2001.","DOI":"10.1128\/AAC.45.3.649-659.2001"},{"key":"e_1_3_1_274_2","doi-asserted-by":"crossref","unstructured":"Merril CR Scholl D Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2: 489\u2013497 http:\/\/dx.doi.org\/10.1038\/nrd1111.","DOI":"10.1038\/nrd1111"},{"key":"e_1_3_1_275_2","doi-asserted-by":"crossref","unstructured":"Fernebro J. 2011. Fighting bacterial infections-future treatment options. Drug Resist Updat 14: 125\u2013139 http:\/\/dx.doi.org\/10.1016\/j.drup.2011.02.001.","DOI":"10.1016\/j.drup.2011.02.001"},{"key":"e_1_3_1_276_2","doi-asserted-by":"crossref","unstructured":"Vuong C Yeh AJ Cheung GY Otto M. 2016. Investigational drugs to treat methicillin-resistant Staphylococcus aureus . Expert Opin Investig Drugs 25: 73\u201393 http:\/\/dx.doi.org\/10.1517\/13543784.2016.1109077.","DOI":"10.1517\/13543784.2016.1109077"},{"key":"e_1_3_1_277_2","doi-asserted-by":"crossref","unstructured":"Rolinson GN. 1998. Forty years of beta-lactam research. J Antimicrob Chemother 41: 589\u2013603 http:\/\/dx.doi.org\/10.1093\/jac\/41.6.589.","DOI":"10.1093\/jac\/41.6.589"},{"key":"e_1_3_1_278_2","doi-asserted-by":"crossref","unstructured":"Papp-Wallace KM Endimiani A Taracila MA Bonomo RA. 2011. Carbapenems: past present and future. Antimicrob Agents Chemother 55: 4943\u20134960 http:\/\/dx.doi.org\/10.1128\/AAC.00296-11.","DOI":"10.1128\/AAC.00296-11"},{"key":"e_1_3_1_279_2","doi-asserted-by":"crossref","unstructured":"Reynolds PE. 1989. Structure biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8: 943\u2013950 http:\/\/dx.doi.org\/10.1007\/BF01967563.","DOI":"10.1007\/BF01967563"},{"key":"e_1_3_1_280_2","doi-asserted-by":"crossref","unstructured":"Zhanel GG Love R Adam H Golden A Zelenitsky S Schweizer F Gorityala B Lagac\u00e9-Wiens PR Rubinstein E Walkty A Gin AS Gilmour M Hoban DJ Lynch JP III Karlowsky JA. 2015. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens. Drugs 75: 253\u2013270 http:\/\/dx.doi.org\/10.1007\/s40265-015-0352-7. [PubMed]","DOI":"10.1007\/s40265-015-0352-7"},{"key":"e_1_3_1_281_2","doi-asserted-by":"crossref","unstructured":"Moellering RC Jr. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138: 135\u2013142 http:\/\/dx.doi.org\/10.7326\/0003-4819-138-2-200301210-00015. [PubMed]","DOI":"10.7326\/0003-4819-138-2-200301210-00015"},{"key":"e_1_3_1_282_2","doi-asserted-by":"crossref","unstructured":"Gaynor M Mankin AS. 2003. Macrolide antibiotics: binding site mechanism of action resistance. Curr Top Med Chem 3: 949\u2013961 http:\/\/dx.doi.org\/10.2174\/1568026033452159.","DOI":"10.2174\/1568026033452159"},{"key":"e_1_3_1_283_2","doi-asserted-by":"crossref","unstructured":"Mast Y Wohlleben W. 2014. Streptogramins: two are better than one! Int J Med Microbiol 304: 44\u201350 http:\/\/dx.doi.org\/10.1016\/j.ijmm.2013.08.008. [PubMed]","DOI":"10.1016\/j.ijmm.2013.08.008"},{"key":"e_1_3_1_284_2","doi-asserted-by":"crossref","unstructured":"Sp\u00edzek J Novotn\u00e1 J \u0158ezanka T. 2004. Lincosamides: chemical structure biosynthesis mechanism of action resistance and applications. Adv Appl Microbiol 56: 121\u2013154 http:\/\/dx.doi.org\/10.1016\/S0065-2164(04)56004-5.","DOI":"10.1016\/S0065-2164(04)56004-5"},{"key":"e_1_3_1_285_2","doi-asserted-by":"crossref","unstructured":"Yunis AA. 1988. Chloramphenicol: relation of structure to activity and toxicity. Annu Rev Pharmacol Toxicol 28: 83\u2013100 http:\/\/dx.doi.org\/10.1146\/annurev.pa.28.040188.000503. [PubMed]","DOI":"10.1146\/annurev.pa.28.040188.000503"},{"key":"e_1_3_1_286_2","doi-asserted-by":"crossref","unstructured":"Curbete MM Salgado HRN. 2016. A critical review of the properties of fusidic acid and analytical methods for its determination. Crit Rev Anal Chem 46: 352\u2013360 http:\/\/dx.doi.org\/10.1080\/10408347.2015.1084225. [PubMed]","DOI":"10.1080\/10408347.2015.1084225"},{"key":"e_1_3_1_287_2","doi-asserted-by":"crossref","unstructured":"Masters PA O\u2019Bryan TA Zurlo J Miller DQ Joshi N. 2003. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 163: 402\u2013410 http:\/\/dx.doi.org\/10.1001\/archinte.163.4.402. [PubMed]","DOI":"10.1001\/archinte.163.4.402"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.GPP3-0057-2018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.GPP3-0057-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T03:20:20Z","timestamp":1646709620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/microbiolspec.GPP3-0057-2018"}},"subtitle":[],"editor":[{"given":"Vincent A.","family":"Fischetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Richard P.","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Joseph J.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Daniel A.","family":"Portnoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Miriam","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Julian I.","family":"Rood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":286,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,12]]}},"alternative-id":["10.1128\/microbiolspec.GPP3-0057-2018"],"URL":"https:\/\/doi.org\/10.1128\/microbiolspec.gpp3-0057-2018","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"2018-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"7.2.18"}}